Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
An antigen solution emulsified in mineral oil. The complete form is made up of killed, dried mycobacteria, usually M. tuberculosis, suspended in the oil phase. It is effective in stimulating cell-mediated immunity (IMMUNITY, CELLULAR) and potentiates the production of certain IMMUNOGLOBULINS in some animals. The incomplete form does not contain mycobacteria.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Tumors or cancer of the human BREAST.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Agents that aid or increase the action of the principle drug (DRUG SYNERGISM) or that affect the absorption, mechanism of action, metabolism, or excretion of the primary drug (PHARMACOKINETICS) in such a way as to enhance its effects.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Tumors or cancer of the LUNG.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
An organoplatinum compound that possesses antineoplastic activity.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Antimetabolites that are useful in cancer chemotherapy.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
Organic compounds which contain platinum as an integral part of the molecule.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
A malignant epithelial tumor with a glandular organization.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Elements of limited time intervals, contributing to particular results or situations.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A decrease in the number of NEUTROPHILS found in the blood.
A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
The forcible expulsion of the contents of the STOMACH through the MOUTH.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Transplantation of an individual's own tissue from one site to another site.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
An alkylating agent of value against both hematologic malignancies and solid tumors.
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.
Tumors or cancer located in bone tissue or specific BONES.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Tumors or cancer of the STOMACH.
The return of a sign, symptom, or disease after a remission.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
Tumors or cancer of the LIVER.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Inorganic compounds which contain platinum as the central atom.
Surgical procedure to remove one or both breasts.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
Tumors or cancer of the COLON.
A cell line derived from cultured tumor cells.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
Tumors or cancer of the PERITONEUM.
Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)
Drugs used to prevent NAUSEA or VOMITING.
An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6)
Antibodies produced by a single clone of cells.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
An anthracenedione-derived antineoplastic agent.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
Cyclic hydrocarbons that contain multiple rings and share one or more atoms.
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
A subspecialty of internal medicine concerned with the study of neoplasms.
Tumors or cancer of the RECTUM.
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Antagonist of urate oxidase.
Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.
A general term for various neoplastic diseases of the lymphoid tissue.
Delivery of medications through the nasal mucosa.
Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
The giving of drugs, chemicals, or other substances by mouth.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
A subnormal level of BLOOD PLATELETS.
A radiosensitive, malignant neoplasm of the testis, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad. There are three variants: classical (typical), the most common type; anaplastic; and spermatocytic. The classical seminoma is composed of fairly well differentiated sheets or cords of uniform polygonal or round cells (seminoma cells), each cell having abundant clear cytoplasm, distinct cell membranes, a centrally placed round nucleus, and one or more nucleoli. In the female, a grossly and histologically identical neoplasm, known as dysgerminoma, occurs. (Dorland, 27th ed)
Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)
Treatment that combines chemotherapy with radiotherapy.
The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.
Platinum. A heavy, soft, whitish metal, resembling tin, atomic number 78, atomic weight 195.09, symbol Pt. (From Dorland, 28th ed) It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae".
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
Clinical protocols used to inhibit the growth or spread of NEOPLASMS.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
ARTHRITIS that is induced in experimental animals. Immunological methods and infectious agents can be used to develop experimental arthritis models. These methods include injections of stimulators of the immune response, such as an adjuvant (ADJUVANTS, IMMUNOLOGIC) or COLLAGEN.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
Proteins prepared by recombinant DNA technology.
Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
Antibodies obtained from a single clone of cells grown in mice or rats.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Tumors or cancer of the URINARY BLADDER.
Removal of only enough breast tissue to ensure that the margins of the resected surgical specimen are free of tumor.
Tumors or cancer of the MEDIASTINUM.
Excision of the whole (total gastrectomy) or part (subtotal gastrectomy, partial gastrectomy, gastric resection) of the stomach. (Dorland, 28th ed)
A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Used for excision of the urinary bladder.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Disorders of the blood and blood forming tissues.
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
The period before MENOPAUSE. In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.
Antineoplastic agent especially effective against malignant brain tumors. The resistance which brain tumor cells acquire to the initial effectiveness of this drug can be partially overcome by the simultaneous use of membrane-modifying agents such as reserpine, calcium antagonists such as nicardipine or verapamil, or the calmodulin inhibitor, trifluoperazine. The drug has also been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms.
Tumors or cancer of the ESOPHAGUS.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
Tumors or cancer of the NASOPHARYNX.
A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects.
A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
An anti-inflammatory 9-fluoro-glucocorticoid.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
A malignant ovarian neoplasm, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad. It is the counterpart of the classical seminoma of the testis, to which it is both grossly and histologically identical. Dysgerminomas comprise 16% of all germ cell tumors but are rare before the age of 10, although nearly 50% occur before the age of 20. They are generally considered of low-grade malignancy but may spread if the tumor extends through its capsule and involves lymph nodes or blood vessels. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1646)
Administration of the total dose of radiation (RADIATION DOSAGE) in parts, at timed intervals.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
Nonsusceptibility to the pathogenic effects of foreign microorganisms or antigenic substances as a result of antibody secretions of the mucous membranes. Mucosal epithelia in the gastrointestinal, respiratory, and reproductive tracts produce a form of IgA (IMMUNOGLOBULIN A, SECRETORY) that serves to protect these ports of entry into the body.
An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).

Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. (1/4884)

Epithelial ovarian cancer (EOC) has a high mortality rate, which is due primarily to the fact that early clinical symptoms are vague and nonspecific; hence, this disease often goes undetected and untreated until in its advanced stages. Sensitive and reliable methods for detecting earlier stages of EOC are, therefore, urgently needed. Epidermal growth factor (EGF) is a ligand for EGF receptor (ErbB1); this receptor is the product of the c-erbB1 proto-oncogene. ErbB1 overexpression is common in human ovarian carcinoma-derived cell lines and tumors, in which overexpression is thought to play a critical role in tumor etiology and progression. Furthermore, ErbB1 overexpression is associated with disease recurrence and decreased patient survival. Recently, we have developed an acridinium-linked immunosorbent assay that detects a approximately 110-kDa soluble analogue of ErbB1, ie., sErbB1, in serum samples from healthy men and women (A. T. Baron, et al., J. Immunol. Methods, 219: 23-43, 1998). Here, we demonstrate that serum p110 sErbB1 levels are significantly lower in EOC patients with stage III or IV disease prior to (P < 0.0001) and shortly after (P < 0.0001) cytoreductive staging laparotomy than in healthy women of similar ages, whereas EGF levels are significantly higher than those of age-matched healthy women only in serum samples collected shortly after tumor debulking surgery (P < 0.0001). We observe that the preoperative serum sErbB1 concentration range of advanced stage EOC patients barely overlaps with the serum sErbB1 concentration range of healthy women. In addition, we show that serum sErbB1 and EGF levels changed temporally for some EOC patients who were surgically debulked of tumor and who provided a second serum sample during the course of combination chemotherapy. Finally, we observe a significant positive association between sErbB1 and EGF levels only in serum samples of EOC patients collected prior to cytoreductive surgery (correlation coefficient = 0.61968; P = 0.0027). These data suggest that epithelial ovarian tumors concomitantly affect serum sErbB1 and EGF levels. In conclusion, these data indicate that serum sErbB1 and EGF (postoperative only) levels are significantly different between EOC patients and healthy women and that altered and/or changing serum sErbB1 and EGF levels may provide important diagnostic and/or prognostic information useful for the management of patients with EOC.  (+info)

Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. (2/4884)

To determine the effectiveness of non-cross-resistant late-consolidation chemotherapy in locally advanced breast cancer (LABC) and stage IV breast cancer, we review our experience with two regimens. Between 1985 and 1991, we enrolled 56 patients with LABC, who were treated with a doxorubicin-based adjuvant regimen, followed by a late-consolidation non-cross-resistant regimen containing methotrexate, 5-fluorouracil, cisplatin, and cyclophosphamide. Between 1985 and 1996, a total of 45 patients with limited stage IV breast cancer underwent surgical excision of all evaluable disease, making them metastatic (stage IV) with no evaluable disease. Surgery was followed by a doxorubicin-containing regimen and then a late-consolidation non-cross-resistant regimen, which was either methotrexate, 5-fluorouracil, cisplatinum, and cyclophosphamide or 5-fluorouracil, mitomycin, etoposide, and cisplatin. Twenty-four patients with limited bone metastases that were unresectable were treated with a doxorubicin-containing regimen, radiation therapy to all sites of disease, and then one of the two late non-cross-resistant regimens. With a median follow-up of 84 months, 78% of patients with LABC are alive, and 68% are free of disease. After a median follow-up of 44 months, 53% of patients with stage IV with no evaluable disease are alive and free of disease. The use of non-cross-resistant late-consolidation chemotherapy is an effective strategy in the treatment of patients with LABC and selected patients with limited stage IV breast cancer.  (+info)

Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. (3/4884)

Necrosis is a common feature of invasive carcinoma of the breast and is caused by chronic ischaemia leading to infarction. Although necrosis was previously assumed to be due to a generally poor blood supply in the tumour, in this study we show that it is present in tumours with focal areas of high vascular density situated away from the actual sites of necrosis. This may account, in part, for the previous observation that necrosis is linked to poor prognosis in this disease. Highly angiogenic tumours often display blood vessel shunting from one tumour area to another, which further exacerbates ischaemia and the formation of tumour necrosis. We have recently demonstrated that high focal microphage infiltration into breast tumours is significantly associated with increased tumour angiogenesis and poor prognosis and that the macrophages accumulate in poorly vascularized, hypoxic areas within breast tumours. In order to investigate the interactions of macrophages with chronic ischaemia (as reflected by the presence of necrosis) and angiogenesis in breast tumours, we quantified the levels of these three biological parameters in a series of 109 consecutive invasive breast carcinomas. We found that the degree of tumour necrosis was correlated with both microphage infiltration (Mann-Whitney U, P-value = 0.0009; chi-square, P-value = 0.01) and angiogenesis (Mann-Whitney U P-value = 0.0008, chi square P-value = 0.03). It was also observed that necrosis was a feature of tumours possessing an aggressive phenotype, i.e. high tumour grade (chi-square, P-value < 0.001), larger size (Mann-Whitney U, P-value = 0.003) and low oestrogen receptor status (Mann-Whitney U, P-value = 0.008; chi-square, P-value < 0.008). We suggest, therefore, that aggressive tumours rapidly outgrow their vascular supply in certain areas, leading to areas of prolonged hypoxia within the tumour and, subsequently, to necrosis. This, in turn, may attract macrophages into the tumour, which then contribute to the angiogenic process, giving rise to an association between high levels of angiogenesis and extensive necrosis.  (+info)

Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. (4/4884)

PURPOSE: From 1986 to 1992, "eight-drugs-in-one-day" (8-in-1) chemotherapy both before and after radiation therapy (XRT) (54 Gy tumor/36 Gy neuraxis) was compared with vincristine, lomustine (CCNU), and prednisone (VCP) after XRT in children with untreated, high-stage medulloblastoma (MB). PATIENTS AND METHODS: Two hundred three eligible patients with an institutional diagnosis of MB were stratified by local invasion and metastatic stage (Chang T/M) and randomized to therapy. Median time at risk from study entry was 7.0 years. RESULTS: Survival and progression-free survival (PFS) +/- SE at 7 years were 55%+/-5% and 54%+/-5%, respectively. VCP was superior to 8-in-1 chemotherapy, with 5-year PFS rates of 63%+/-5% versus 45%+/-5%, respectively (P = .006). Upon central neuropathology review, 188 patients were confirmed as having MB and were the subjects for analyses of prognostic factors. Children aged 1.5 to younger than 3 years had inferior 5-year estimates of PFS, compared with children 3 years old or older (P = .0014; 32%+/-10% v 58%+/-4%, respectively). For MB patients 3 years of age or older, the prognostic effect of tumor spread (MO v M1 v M2+) on PFS was powerful (P = .0006); 5-year PFS rates were 70%+/-5%, 57%+/-10%, and 40%+/-8%, respectively. PFS distributions at 5 years for patients with M0 tumors with less than 1.5 cm2 of residual tumor, versus > or = 1.5 cm2 of residual tumor by scan, were significantly different (P = .023; 78%+/-6% v 54%+/-11%, respectively). CONCLUSION: VCP plus XRT is a superior adjuvant combination compared with 8-in-1 chemotherapy plus XRT. For patients with M0 tumors, residual tumor bulk (not extent of resection) is a predictor for PFS. Patients with M0 tumors, > or = 3 years with < or = 1.5 cm2 residual tumor, had a 78%+/-6% 5-year PFS rate. Children younger than 3 years old who received a reduced XRT dosage had the lowest survival rate.  (+info)

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. (5/4884)

PURPOSE: To assess whether pamidronate can reduce the frequency of skeletal morbidity in women with lytic bone metastases from breast cancer treated with hormone therapy. PATIENTS AND METHODS: Three hundred seventy-two women with breast cancer who had at least one lytic bone lesion and who were receiving hormonal therapy were randomized to receive 90 mg of pamidronate or placebo as a 2-hour intravenous infusion given in double-blind fashion every 4 weeks for 24 cycles. Patients were evaluated for skeletal complications: pathologic fractures, spinal cord compression, irradiation of or surgery on bone, or hypercalcemia. The skeletal morbidity rate (the ratio of the number of skeletal complications to the time on trial) was the primary efficacy variable. Bone pain, use of analgesics, quality of life, performance status, bone tumor response, and biochemical parameters were also evaluated. RESULTS: One hundred eighty-two patients who received pamidronate and 189 who received placebo were assessable. The skeletal morbidity rate was significantly reduced at 12, 18, and 24 cycles in patients treated with 90 mg of pamidronate (P = .028, .023, and .008, respectively). At 24 cycles, the proportion of patients having had any skeletal complication was 56% in the pamidronate group and 67% in the placebo group (P = .027). The time to the first skeletal complication was longer for patients receiving pamidronate than for those given placebo (P = .049). There was no statistical difference in survival or in objective bone response rate. Pamidronate was well tolerated. CONCLUSION: Treatment with 90 mg of pamidronate as a 2-hour intravenous infusion every 4 weeks in addition to hormonal therapy significantly reduces skeletal morbidity from osteolytic metastases.  (+info)

Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. (6/4884)

PURPOSE: To evaluate the efficacy and tolerance of combined irinotecan and oxaliplatin in patients with advanced colorectal cancer pretreated with leucovorin-modulated fluoropyrimidines. PATIENTS AND METHODS: Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within 6 months after discontinuing palliative chemotherapy with fluoropyrimidines/leucovorin, were enrolled onto this study. Treatment consisted of oxaliplatin 85 mg/m2 on days 1 + 15 and irinotecan 80 mg/m2 on days 1 + 8 + 15 every 4 weeks. Depending on the absolute neutrophil counts (ANC) on the day of scheduled chemotherapeutic drug administration, a 5-day course of granulocyte colony-stimulating factor (G-CSF) 5 microg/kg/d was given. RESULTS: The overall response rate was 42% for all 36 assessable patients (95% confidence interval, 26% to 59%), including two complete remissions (6%). Thirteen additional patients (36%) had stable disease, and only eight (22%) progressed. The median time to treatment failure was 7.5 months (range, 1 to 13.5+ months). After a median follow-up time of 14 months, 19 patients (53%) are still alive. Hematologic toxicity was commonly observed, although according to the ANC-adapted use of G-CSF (in 31 patients during 81 of 174 courses), it was generally mild: grade 3 and 4 granulocytopenia occurred in only five and two cases, respectively. The most frequent nonhematologic adverse reactions were nausea/emesis and diarrhea, which were rated severe in 17% and 19%, respectively. CONCLUSION: Our data suggest that the combination of irinotecan and oxaliplatin with or without G-CSF has substantial antitumor activity in patients with progressive fluoropyrimidine/leucovorin-pretreated colorectal cancer. Overall toxicity was modest, with gastrointestinal symptoms constituting the dose-limiting side effects. Further evaluation of this regimen seems warranted.  (+info)

Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. (7/4884)

PURPOSE: To compare the effect of pathologic sentinel lymph node (SLN) status with that of other known prognostic factors on recurrence and survival in patients with stage I or II cutaneous melanoma. PATIENTS AND METHODS: We reviewed the records of 612 patients with primary cutaneous melanoma who underwent lymphatic mapping and SLN biopsy between January 1991 and May 1995 to determine the effects of tumor thickness, ulceration, Clark level, location, sex, and SLN pathologic status on disease-free and disease-specific survival. RESULTS: In the 580 patients in whom lymphatic mapping and SLN biopsy were successful, the SLN was positive by conventional histology in 85 patients (15%) but negative in 495 patients (85%). SLN status was the most significant prognostic factor with respect to disease-free and disease-specific survival by univariate and multiple covariate analyses. Although tumor thickness and ulceration influenced survival in SLN-negative patients, they provided no additional prognostic information in SLN-positive patients. CONCLUSION: Lymphatic mapping and SLN biopsy is highly accurate in staging nodal basins at risk for regional metastases in primary melanoma patients and identifies those who may benefit from earlier lymphadenectomy. Furthermore, pathologic status of the SLN in these patients with clinically negative nodes is the most important prognostic factor for recurrence. The information from SLN biopsy is particularly helpful in establishing stratification criteria for future adjuvant trials.  (+info)

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). (8/4884)

BACKGROUND: Neoadjuvant chemotherapy improves overall survival and renders possible breast-conserving treatment in locally advanced breast cancer. It was necessary for this method to be evaluated in operable breast tumors too large to be treated immediately by conserving surgery. Initial results of this randomized trial were published in Annals of Oncology (1991). PATIENTS AND METHODS: Women with T2 > 3 cm or T3 N0-1 M0 breast tumors were treated by either initial mastectomy followed by adjuvant chemotherapy, or neoadjuvant chemotherapy followed by adjusted locoregional treatment. Chemotherapy was the same in the two arms. The prognostic and predictive factors of response to chemotherapy were analyzed. RESULTS: Conserving treatments were performed in 63% at the end of neoadjuvant chemotherapy and this rate had decreased to 45% at the median follow-up of 124 months. Survivals are identical in the two treatment groups. Initial clinical tumor size < 40 mm, IHC-ER < 10% and Mib1 > 40% are predictive of tumor response to chemotherapy by uni- and multivariate analyses. For outcome prediction, c-erb-B2 > 0% is the independent prognostic factor for overall and metastasis-free survivals. CONCLUSION: Breast-conserving therapy can be performed in more than half of all cases without alteration of survival, despite a non-negligible rate of local recurrences.  (+info)

In our study, ERCC1 expression provided both prognostic and predictive information in patients with completely resected bladder cancer. Among patients with transitional cell carcinoma of the bladder treated with cystectomy, high tumoral expression of ERCC1 correlated with longer survival in patients without adjuvant chemotherapy and was associated with shorter survival in those with adjuvant chemotherapy. A statistically significant interaction between ERCC1 expression and adjuvant chemotherapy indicated potential benefits of adjuvant chemotherapy in patients with ERCC1-negative tumors.. To date, the role of adjuvant chemotherapy for bladder cancer has been controversial, with no Level 1 evidence supporting adjuvant chemotherapy. In fact, the available data have not demonstrated a clear benefit of adjuvant chemotherapy. Despite mounting evidence favoring neoadjuvant chemotherapy [1-3], physicians are reluctant to adopt its practice as evidenced by only 1.2% of patients with stage III bladder ...
Key Findings. The median number of neoadjuvant cycles of FOLFIRINOX was six.. Among the 520 patients, 343 (66.0%) received adjuvant chemotherapy, including FOLFIRINOX in 19.8%, gemcitabine-based chemotherapy in 58.6%, capecitabine in 4.1%, a combination or other agents in 13.1%, and unknown chemotherapy in 4.4%. A total of 177 patients received no adjuvant chemotherapy.. Median overall survival was 29 months in the adjuvant therapy group vs 29 months in the no adjuvant therapy group (hazard ratio [HR] = 0.99; 95% confidence interval [CI] = 0.77-1.28, P = .93). On multivariate analysis, the hazard ratio was 0.85 (95% CI = 0.35-2.10, P = .73).. On multivariate analysis, only the interaction term of nodal status with adjuvant chemotherapy was significant. Among the 50% vs 38% of patients with pathology-proven, node-positive disease, median overall survival was 26 months with adjuvant chemotherapy vs 13 months with no adjuvant chemotherapy (HR = 0.41, 95% CI = 0.22-0.75, P = .004). Among patients ...
Giuliani, F; Marco, A D.; Casazza, A M.; and Savi, G, Combination chemotherapy and surgical adjuvant chemotherapy on ms-2 sarcoma and lung metastases in mice. (1979). Subject Strain Bibliography 1979. 165 ...
TY - JOUR. T1 - Surgery and adjuvant chemotherapy use among veterans with colon cancer. T2 - Insights from a California study. AU - Hynes, Denise M.. AU - Tarlov, Elizabeth. AU - Durazo-Arvizu, Ramon. AU - Perrin, Ruth. AU - Zhang, Qiuying. AU - Weichle, Thomas. AU - Ferreira, M. Rosario. AU - Lee, Todd. AU - Benson, Al B.. AU - Bhoopalam, Nirmala. AU - Bennett, Charles L.. PY - 2010/5/20. Y1 - 2010/5/20. N2 - Purpose: US veterans have been shown to be a vulnerable population with high cancer rates, and cancer care quality in Veterans Affairs (VA) hospitals is the focus of a congressionally mandated review. We examined rates of surgery and chemotherapy use among veterans with colon cancer at VA and non-VA facilities in California to gain insight into factors associated with quality of cancer care. Methods: A retrospective cohort of incident colon cancer patients from the California Cancer Registry, who were ≥ 66 years old and eligible to use VA and Medicare between 1999 and 2001, were observed ...
TY - JOUR. T1 - Optimizing adjuvant chemotherapy in early-stage breast cancer.. AU - Perez, Edith. AU - Muss, Hyman B.. PY - 2005/12. Y1 - 2005/12. N2 - Mortality in breast cancer has declined in the past decade, owing to advances in diagnosis, surgery, radiotherapy, and systemic treatments. Adjuvant chemotherapy has had a major effect on increasing survival in women with locoregional breast cancer. Like all treatments, adjuvant chemotherapy is a work in progress, and it has evolved from single oral agents to complex multidrug regimens. The choice of regimens is not without controversy, however, and several have been shown to be more effective than others, especially in patients who are at high risk for recurrence. The taxanes paclitaxel and docetaxel (Taxotere) have been shown to be effective in the adjuvant setting, and they have also been shown to improve the outcomes in node-positive disease. Both disease-free and overall survival are greater with doxorubicin, paclitaxel, and ...
The study is designed to investigate the effect of postoperative adjuvant chemotherapy in prevention of tumor recurrence and metastasis for hepatocellul
A new study conducted by ASCO in collaboration with the American Cancer Society (ACS) and the American Society for Radiation Oncology (ASTRO) and published in the Journal of Clinical Oncology1 found that patients who have to travel farther to appointments are less likely to receive adjuvant chemotherapy, regardless of whether or not they are insured.. Evidence-based treatment guidelines recommend the use of adjuvant chemotherapy in many cancer patients within 90 days after surgery. But studies show that in many cases, patients do not receive it.. To explore the role geographic access to care plays, researchers compared patients travel distance, insurance status, and an areas density of oncologists to the likelihood patients received adjuvant chemotherapy within 90 days of surgery for colon cancer. The data used in the study captured about 70% of newly diagnosed cancer cases in the United States.. Of 34,694 patients in the study cohort, three-quarters (75.7%) received adjuvant chemotherapy ...
Operation is the only curative treatment for gastric cancer patients. However, the rate of recurrence is high up to 60%. The 5 years overall survival of patient at stage IIIb or more advanced stage is still poor and approximately 8-28%. Adjuvant chemotherapy is critical for improving efficacy further. Unfortunately, the optimal adjuvant regimen is not identified yet. The standard adjuvant treatments of American and European patients are not accepted widely in Asia area because of different operation procedure and patients tolerability. Results of two critical trials indicated that S-1 alone as Japanese standard adjuvant chemotherapy could not improve the survival of stage IIIb advanced stage gastric cancer patients while the Korean standard regimen XELOX could. This implied that the more intensive chemotherapy must be used for the patients with higher risk of relapse. The proportion of the stage IIIb-IIIc Chinese gastric cancer patients is much larger than that of Japan and Korean. However, no ...
With very few exceptions, initial therapy for colon cancer is adequate surgical resection. Subsequent surgical and pathologic staging will dictate the need for adjuvant therapy. Currently, Stage I colon cancer patients enjoy a high cure rate after surgery alone (,80%), and there is no evidence that these patients will benefit from any adjuvant therapy. Large randomized clinical trials have been more interested in Stage II and Stage III colon cancer patients whose cure rate can be as low as 30% after surgery alone. Early chemotherapy trials for colon cancer used the chemotherapeutic agents available at the time. Eventually, fluorinated pyrimidines (5-Fluorouracil or 5-FU) were shown to have activity against metastatic colorectal cancer. This finding led to several trials evaluating 5-FU as adjuvant therapy for high risk patients after surgery (Stage II and III colon cancer). In 1988, Buyse and colleagues(4) published a meta-analysis of all randomized controlled trials of adjuvant therapy with ...
Barrett-Lee, P., Ellis, P., Bliss, J., TACT (Taxotere as Adjuvant Chemotherapy Trial) Management Group (includes John Yarnold) (2002) Duration of adjuvant chemotherapy; Anthracyclines, taxanes and novel agents - More or less. JOURNAL OF CLINICAL ONCOLOGY, 14 (4). pp. 263-266. ISSN 0732-183X ...
BACKGROUND: Although the benefit from adjuvant chemotherapy has been established clearly in patients with Stage III colon carcinoma, the degree to which elderly patients with colon carcinoma can tolerate such therapy generally has remained unknown. METHODS: The authors reviewed all patients in their Tumor Registry with Stage II and Stage III adenocarcinoma of the colon who underwent potentially curative resection for their disease at the Geisinger Medical Center between January 1990 and September 2000. One hundred twenty patients underwent complete resection of their colon carcinoma and received 5-fluorouracil-based (5-FU) adjuvant chemotherapy. RESULTS: The 5-year disease free survival rate for patients age | or =65 years (Group A) was 70% compared with 56% for patients age | 65 years (Group B) (P = 0.085). The 5-year overall survival rate for patients in Group B was 77% compared with 62% for the patients in Group A (P = 0.143). In a Cox regression model, age was not a predictor of disease free
Among the total 1,036 breast cancer cases, 190 (18.3%) were cases of TNBC. NCCN guidelines and the St. Gallen consensus conference recommend adjuvant chemotherapy for TNBC [26], although a specific regimen for such adjuvant treatment has yet to be presented. In the 190 TNBC cases of the present study, patients undergoing surgery plus adjuvant therapy had a more favorable prognosis than those receiving surgery alone, only among those with Stage II disease, suggesting that adjuvant therapy is indeed useful for TNBC patients as the NCCN recommends, and is most relevant at Stage II. In the adjuvant therapy group, both univariate and multivariate analysis showed no significant difference in prognosis between the anthracyclin-based regimen and 5FU-based regimen, although patients with the former regimen showed a trend-level improvement in prognosis over those with the latter. Larger studies might be necessary to clarify the prognoses of anthracyclin-based regimen and 5FU-based regimen.. Since reliable ...
Ethnic and socioeconomic inequities in use of breast cancer adjuvant therapy are well documented in many countries including the USA, and are known to contribute to lower breast cancer survival among minority ethnic and socioeconomically deprived women. We investigated ethnic and socioeconomic inequities in use of adjuvant radiotherapy and chemotherapy in a cohort of women with invasive breast cancer in New Zealand. All women with newly diagnosed invasive breast cancer during 1999-2012 were identified from the Waikato Breast Cancer Register. Rates of chemotherapy use and radiotherapy use were assessed in women who were deemed to be eligible for chemotherapy (n = 1212) and radiotherapy (n = 1708) based on guidelines. Factors associated with use of chemotherapy and radiation therapy were analysed in univariate and multivariate regression models, adjusting for covariates. Overall, rates of chemotherapy and radiotherapy use were 69% (n = 836) and 87.3% (n = 1491), respectively. In the multivariate model,
Chemotherapy (+/- Radiation). Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.. chemotherapy: Given within 10 weeks after surgery.. ...
Objectives: The 21-Gene Recurrence Score (RS) assay helps guide adjuvant chemotherapy use for patients with breast cancer, and is predicted to reduce overall chemotherapy use. Little is known about recent patterns of testing in the Medicare program and the impact of testing on chemotherapy use as a function of patient age. Materials and Methods: We conducted a national claims-based study of Medicare beneficiaries age ≥66 years. We assessed trends in assay use (using multivariable regression), adjuvant chemotherapy use, and associated expenditures, for all patients and for two age strata: age 66-74 years and 75-94 years. Geographic variations in assay adoption and regional-level correlation between assay and chemotherapy use were measured. Results: We identified 132,222 women who underwent breast surgery from 2008-2011. Assay use increased from 9.0% to 17.2% from 2008-2011 (p|.001), but chemotherapy use remained stable at 12.5% (p=.49). In younger patients, assay use increased from 14.3% to 23.7% (p|
Background: The potential benefit of adjuvant chemotherapy in patients with Stage IA triple negative breast cancer (TNBC) has not been defined. In general, patients with T1a and T1b lesions have not been included in adjuvant chemotherapy trials and the inclusion of T1c tumors has been limited. In this study using National Cancer Data Base (NCDB) we investigated the actual use of adjuvant chemotherapy in Stage IA TNBC patients relative to tumor size (T1a, T1b, T1c) and report their survival outcomes.. Patients and Methods: Using NCDB we evaluated a cohort of 13,065 women with TNBC diagnosed between 2010-2012 who had American Joint Committee on Cancer Stage IA (node-negative with pathological T1a, T1b or T1c) tumors. Overall survival (OS) was the primary outcome variable. Based on the tumor size, patients were stratified on receipt of adjuvant chemotherapy or not. Patients were also stratified according to receipt of adjuvant radiation, radiation with boost, or none. Other adjusted variables ...
This study is investigating low dose versus standard dose capecitabine adjuvant chemotherapy for chinese elderly patients with stage II/III colorectal
Background: Adjuvant therapy for resected pancreatic adenocarcinoma was given a category 1 NCCN recommendation in 2000, yet many patients do not receive chemotherapy after definitive surgery. Whether sociodemographic disparities exist for receipt of adjuvant chemotherapy is poorly understood. Methods: The National Cancer Database was used to identify patients diagnosed with nonmetastatic pancreatic adenocarcinoma who underwent definitive surgery from 2004 through 2015. Multivariable logistic regression defined the adjusted odds ratio (aOR) and associated 95% CI of receipt of adjuvant chemotherapy. Among patients receiving chemotherapy, multivariable logistic regression assessed the odds of treatment with multiagent chemotherapy. Results: Among 18,463 patients, 11,288 (61.1%) received any adjuvant chemotherapy. Sociodemographic factors inversely associated with receipt of any adjuvant chemotherapy included uninsured status (aOR, 0.61; 95% CI, 0.50-0.74), Medicaid insurance (aOR, 0.66; 95% CI, ...
The expression of p-glycoprotein (p-gp) was evaluated in pre- and post-chemotherapy states after the administration of adriamycin-based chemotherapy in 24 gastric cancer patients. Among them, group A was composed of twelve patients who relapsed after surgery plus adjuvant chemotherapy and group B wa...
Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.
Shiroda (capecitabine) can be used for adjuvant chemotherapy after breast cancer surgery?,Patients: 5.10 underwent total resection and left breast sentinel, pathology showed 3 infiltrating ductal carcinoma, tumor diameter 1.5cm, n
Although there has been some progress in chemotherapy for metastatic gastric cancer, no standard regimen of adjuvant chemotherapy is available, and many
Based on the results of 3 adjuvant trials (MOSAIC,20 NSABP-C-07,21 and XELOXA22), oxaliplatin-based combinational chemotherapy is considered the standard of care for patients with stage III colon cancer, offering a 4% overall survival (OS) benefit over 5FU/LV at 6 years. However, the additional benefit of oxaliplatin in older patients appears to be attenuated. Subset analyses of MOSAIC and NSABP C-07 trials showed no significant benefit in OS with the addition of oxaliplatin in patients age 70 or older (MOSAIC mortality hazard ratio [HR] = 1.10; 95% confidence interval [CI], 0.73-1.65; for NSABP-C-07, HR = 1.32; 95% CI, 1.03-1.70).20,21 In contrast, a subgroup analysis of XELOXA, a study that evaluated the use of oral capecitabine in combination with oxaliplatin versus bolus 5FU/LV, the benefits of disease-free survival (DFS) were maintained regardless of age, but no significant OS benefit was shown.22 In an analysis using the ACCENT23 database of 2575 patients age ≥70 years using ...
Similarly claims that chemotherapy have produced increased percentage 5-year survival for other cancers, such as cancer of the large bowel1, could be attributed to poor methodology because none of these cancers exhibited a divergence between incidence and mortality rate curves over time5.. Ulrich Abel reviewed the evidence for the efficacy of chemotherapy for invasive epithelial cancer6, the types of cancer for which chemotherapy is most commonly used. He concluded that there was some evidence from randomised trials that chemotherapy increased survival only for small-cell lung cancer. Yet even here the gain in survival was measured in weeks or months.. Adjuvant chemotherapy for breast cancer It is widely claimed that adjuvant chemotherapy extends survival with late-stage breast cancer. For example, in a letter in the Sydney Morning Herald of 22 November 1996 Professor Allan Langlands claimed that the results of a meta-analysis of more than 100 trials of adjuvant systemic therapy in many ...
Sometimes a treatment may be started at a lower dose or the dose needs to be changed during treatment. There may also be times when your treatment is delayed. This can happen if your doctor thinks you are likely to have severe side effects, if you get severe side effects, if your blood counts are affected and causing delays in treatment, or if you are finding it hard to cope with the treatment. This is called a dose reduction, dose change or treatment delay. Your doctor will explain if you need any changes or delays to your treatment and the reason why. ...
TY - JOUR. T1 - Editorial Comment on. T2 - Potential Impact of Postoperative Early Complications on the Timing of Adjuvant Chemotherapy in Patients Undergoing Radical Cystectomy: A High-Volume Tertiary Cancer Center Experience. AU - Svatek, Robert S.. AU - Shariat, Shahrokh F.. PY - 2009/1. Y1 - 2009/1. UR - http://www.scopus.com/inward/record.url?scp=56249118335&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=56249118335&partnerID=8YFLogxK. U2 - 10.1016/j.eururo.2008.07.019. DO - 10.1016/j.eururo.2008.07.019. M3 - Comment/debate. C2 - 18640773. AN - SCOPUS:56249118335. VL - 55. SP - 185. EP - 186. JO - European Urology. JF - European Urology. SN - 0302-2838. IS - 1. ER - ...
BACKGROUND: We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer. METHODS: We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles of treatment with either TAC or FAC as adjuvant chemotherapy after surgery. The primary end point was disease-free survival. RESULTS: At a median follow-up of 55 months, the estimated rates of disease-free survival at five years were 75 percent among the 745 patients randomly assigned to receive TAC and 68 percent among the 746 randomly assigned to receive FAC, representing a 28 percent reduction in the risk of relapse (P=0 ...
Abraham, Jean E., Hiller, Louise, Dorling, Leila, Vallier, Anne-Laure, Dunn, Janet A., Bowden, Sarah, Ingle, Susan, Jones, Linda, Hardy, Richard, Twelves, Christopher, Poole, Christopher J., Pharoah, Paul D. P., Caldas, Carlos and Earl, Helena M.. (2015) A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Medicine, 13 (1). 306. ISSN 1741-7015 ...
ROCHESTER, Minnesota-Fluorouracil (5-FU)-based chemotherapy after surgery can be given safely to selected elderly patients with stage II/III colon cancer, and these patients derive the same benefits from the treatment as do their younger counterparts, according to results of a pooled analysis of seven clinical trials. 1
TY - JOUR. T1 - Estimating regimen-specific costs of chemotherapy for breast cancer. T2 - Observational cohort study. AU - Giordano, Sharon H.. AU - Niu, Jiangong. AU - Chavez-MacGregor, Mariana. AU - Zhao, Hui. AU - Zorzi, Daria. AU - Shih, Ya Chen Tina. AU - Smith, Benjamin D.. AU - Shen, Chan. PY - 2016/11/15. Y1 - 2016/11/15. N2 - BACKGROUND: One goal for high-quality patient care is communicating treatment costs to patients, yet cost information can be elusive. This is especially relevant for breast cancer care, for which numerous guideline-concordant adjuvant chemotherapy regimens exist. The objective of the current study was to generate cost estimates for such regimens from payers and patients perspectives in a large, insured US population. METHODS: Adult women who had incident breast cancer diagnosed between 2008 and 2012 (from the MarketScan database), had no secondary malignancy within 1 year of diagnosis, and received chemotherapy within 3 months of diagnosis were included (n = ...
Chemotherapy involves using anti-cancer (cytotoxic) drugs to kill the cancer cells. Chemotherapy is usually used after surgery to destroy any cancer cells that have not been removed. This is called adjuvant chemotherapy. In some cases, you may have chemotherapy before surgery, which is generally used to shrink a large tumour. This is called neo-adjuvant chemotherapy.. Several different drugs are used for chemotherapy and often three are given at once. The choice of drugs and the combination depends on the type of breast cancer and how much it has spread.. Chemotherapy is usually given as an outpatient treatment, which means you will not have to stay in hospital overnight. The drugs are usually given through a drip straight into the blood through a vein. In some cases, you may be given tablets that you can take at home. You may receive chemotherapy sessions once every two to three weeks, over a period of four to eight months, to give your body a rest in between treatments.. The main side effects ...
Chemotherapy involves using anti-cancer (cytotoxic) drugs to kill the cancer cells. Chemotherapy is usually used after surgery to destroy any cancer cells that have not been removed. This is called adjuvant chemotherapy. In some cases, you may have chemotherapy before surgery, which is generally used to shrink a large tumour. This is called neo-adjuvant chemotherapy.. Several different drugs are used for chemotherapy and often three are given at once. The choice of drugs and the combination depends on the type of breast cancer and how much it has spread.. Chemotherapy is usually given as an outpatient treatment, which means you will not have to stay in hospital overnight. The drugs are usually given through a drip straight into the blood through a vein. In some cases, you may be given tablets that you can take at home. You may receive chemotherapy sessions once every two to three weeks, over a period of four to eight months, to give your body a rest in between treatments.. The main side effects ...
目的:分析胃癌根治术后辅助治疗的疗效和副作用。方法:2005年1月至2012年9月在本院接受综合治疗的患者,男性94例,女性62例,平均年龄58.2岁(23~84岁,中位58岁)。所有病例均为手术病理证实为胃癌,按AJCC分期第7版标准,IA期7例,IB期7例,IIA期6例,IIB期19例,IIIA25例,IIIB期34例,IIIC期44例,IV期12例,不详2例。156例均采用根治性切除。12例术后未行任何化疗,142例术后接受各种方案的化疗,其中64例采用多西紫杉醇 + 铂类 + 氟尿嘧啶类(DCF)或表阿霉素 + 铂类 + 氟尿嘧啶类(ECF)三药方案,66例采用铂类 + 氟尿嘧啶类两药方案,9例采用口服替吉奥或卡培他滨单药化疗,1例仅采用铂类 + 氟尿嘧啶类腹腔灌注,2例化疗方案不详。有28例接受术后放疗。结果:中位随访36.5月。3年总生存率为53.5%,3年局部控制率为82.0%,3年无远处转移率53.8%。单因素分析显示T分期(T1-3或T4)
This study assessed the efficacy of adjuvant capecitabine in patients with liver cancer also receiving routine supportive care. The primary measure of interest
TY - JOUR. T1 - PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2(+) Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. AU - Guarneri, Valentina. AU - Dieci, Maria Vittoria. AU - Bisagni, Giancarlo. AU - Brandes, Alba A.. AU - Frassoldati, Antonio. AU - Cavanna, Luigi. AU - Musolino, Antonino. AU - Giotta, Francesco. AU - Rimanti, Anita. AU - Garrone, Ornella. AU - Bertone, Elena. AU - Cagossi, Katia. AU - Nanni, Oriana. AU - Piacentini, Federico. AU - Orvieto, Enrico. AU - Griguolo, Gaia. AU - Curtarello, Matteo. AU - Urso, Loredana. AU - Pare, Laia. AU - Chic, Nuria. AU - DAmico, Roberto. AU - Prat, Aleix. AU - Conte, Pierfranco. PY - 2020/11/15. Y1 - 2020/11/15. N2 - Purpose: We explored the prognostic effect of PIK3CA mutation in HER2(+) patients enrolled in the ShortHER trial. Patients and Methods: The ShortHER trial randomized 1,253 patients with HER2(+) breast cancer to 9 weeks or 1 year of adjuvant trastuzumab combined with ...
TY - JOUR. T1 - Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies. T2 - An analysis of two intergroup trials. AU - Albain, K. S.. AU - Green, S. R.. AU - Lichter, A. S.. AU - Hutchins, L. F.. AU - Wood, W. C.. AU - Henderson, I. C.. AU - Ingle, J. N.. AU - OSullivan, J.. AU - Osborne, C. K.. AU - Martino, S.. PY - 1996. Y1 - 1996. N2 - Purpose: To investigate the frequency of breast-sparing treatment among breast cancer patients subsequently enrolled in national cooperative group studies of adjuvant chemotherapy. Patients and Methods: A data base was formed of 5,172 patients randomized onto two intergroup trials. Lumpectomy rates were analyzed within study-defined risk strata and across geographic regions. Significant predictors of lower lumpectomy usage were determined in multivariate analyses with variables that described patient and disease characteristics, ...
Even if the cancer is advanced and it is not possible to remove it, some surgical techniques may still have a place to ease symptoms. For example, a blockage may be eased by using laser surgery, by inserting a rigid stent (tube), or by stretching the oesophagus (dilatation), which allows food and drink to pass through the blockage to the stomach.. Chemotherapy. Chemotherapy is a treatment of cancer by using anti-cancer medicines which kill cancer cells, or stop them from multiplying. Following surgery you may be given a course of chemotherapy. This aims to kill any cancer cells which may have spread away from the primary tumour. When chemotherapy is used after surgery it is called adjuvant chemotherapy. In some cases chemotherapy is given before surgery, to shrink a large tumour so that surgery is more likely to be successful. This is called neoadjuvant chemotherapy. Radiotherapy. Radiotherapy is a treatment which uses high-energy beams of radiation which are focused on cancerous tissue. This ...
1)To determine whether the addition of erlotinib to gemcitabine adjuvant chemotherapy improves survival as compared to gemcitabine alone following R0 or R1 resection of head of pacreas adenocarcionoma (including adenocarcinoma of the head, neck, and uncinate process ...
Adjuvant therapy begins after surgical removal of the tumour. You will decide with your oncologist on adjuvant treatment such as chemotherapy or radiation.
Anthracycline-based chemotherapies are effective and are widely used as the main postoperative adjuvant chemotherapy for patients with early-stage breast cancer (1-3). However, those treatments are accompanied by a high incidence of nausea and vomiting (4,5), severely compromising the patients QOL. The use of 5HT3 receptor antagonists has become commonplace in recent years, enabling a certain level of control of these symptoms. However, fatigue and decreased physical QOL remain challenging issues in breast cancer patients receiving postoperative adjuvant chemotherapy, and methods for alleviating these symptoms are needed (9). In our earlier single-group open study, in which LEM was coadministered to breast cancer patients who were treated with the FEC75 regimen, the QOL-ACD (24) was used to evaluate the effect of LEM on the patients QOL. The results indicated that coadministration of LEM was effective in improving the patients physical scale in response to the FEC75 regimen. LEM is a BRM ...
TY - JOUR. T1 - Completion of therapy by medicare patients with stage III colon cancer. AU - Dobie, Sharon A.. AU - Baldwin, Laura Mae. AU - Dominitz, Jason A.. AU - Matthews, Barbara. AU - Billingsley, Kevin. AU - Barlow, William. PY - 2006/5/3. Y1 - 2006/5/3. N2 - Background: Certain factors, such as race or age, are known to be associated with variation in initiation of adjuvant chemotherapy for stage III colon cancer, but little is known about what factors are associated with completion of adjuvant therapy. To determine whether predictors of initiation also predict completion, we analyzed Surveillance, Epidemiology, and End Results (SEER) program data linked to Medicare claims. We investigated mortality as a means to testing the validity of the completion measure that we created. Methods: We studied 3193 stage III colon cancer patients whose diagnosis was recorded in 1992-1996 SEER program data linked to 1991-1998 Medicare claims and who initiated adjuvant chemotherapy after colon cancer ...
The multiinstitutional osteosarcoma study (MIOS), a randomized trial of adjuvant therapy for osteosarcoma with a concurrent control group, registered 113 patients from June 1982 to August 1984. Preliminary analysis of the study indicated a significant event-free survival advantage favoring immediate adjuvant chemotherapy, (P less than .001). For patients treated with surgery alone or with surgery and adjuvant chemotherapy, the lungs were involved in more than 80% of the relapses. Patients relapsing after surgery alone tended to relapse earlier (P less than .01), had more pulmonary nodules (P less than .01), and had more frequent bilateral pulmonary involvement (P less than .01) than those treated with immediate postsurgical adjuvant chemotherapy. However, patients relapsing after treatment with surgery alone experienced a significantly longer interval to further disease progression (P less than .01) and improved survival after relapse (P = .01) when compared with patients who relapsed after ...
The standard of care for resected stage II - IIIA non-small-cell lung cancer includes adjuvant chemotherapy based on the results of randomized trials using cisplatin regimens. A recent meta-analysis (Lung Adjuvant Cisplatin Evaluation) showed no surv
PURPOSE: To assess the effect of more extensive radiotherapy and of adjuvant combination chemotherapy on long-term outcome of early-stage Hodgkins disease. METHODS: In a collaborative worldwide systematic overview, individual patient data were centrally reviewed on 1,974 patients in eight randomized trials of more versus less extensive radiotherapy and on 1,688 patients in 13 trials of radiotherapy plus chemotherapy versus radiotherapy alone. Crude mortality data on 226 patients in two other trials of chemotherapy were also reviewed. RESULTS: More extensive radiotherapy reduced the risk of treatment failure (resistant or recurrent disease) at 10 years by more than one third (31.3% v 43.4% failures; P | .00001), but there was no apparent improvement in overall 10-year survival (77.1 % v 77.0% alive). The addition of chemotherapy to radiotherapy halved the 10-year risk of failure (15.8% v 32.7%; P | .00001), with a small, nonsignificant improvement in survival (79.4% v 76.5% alive). This involved a
In this prospective study, we showed that MMR status in colorectal cancer may predict adjuvant chemotherapy response. Thus while in general, patients with stage II or III disease who received 5-FU based adjuvant chemotherapy had a better overall survival and disease free survival, this benefit was found only in patients with MMR competent tumours. Patients with MMR deficient tumours did not have a better survival or disease free survival when they received 5-FU adjuvant chemotherapy. The results remained unchanged when we stratified according to TNM stage. Conversely, when we analysed the efficacy of treatment received according to MMR status, we found that patients with MMR deficient tumours who did not receive adjuvant chemotherapy had a slightly better survival and disease free survival than patients with MMR competent tumours, even though the analysis failed to reach statistical significance.. Several studies have evaluated the benefit of adjuvant chemotherapy according to MMR status of ...
All information about the latest scientific publications of the Clínica Universidad de Navarra. GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment
Among patients with Stage II or Stage III colon cancer, the Oncotype DX colon cancer test provides information about risk of cancer recurrence and may help guide treatment decisions. These results were presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.. Gene expression profiling explores the patterns of genes that are active in tumor cells. Studies suggest that gene expression may provide important information about prognosis or likely response to treatment in several types of cancer. For example, among women with early-stage, estrogen receptor-positive breast cancer, the Oncotype DX breast cancer test has been shown to predict the likelihood of cancer recurrence and the likelihood of benefit from chemotherapy. As a result, the test has been added to medical guidelines for early-stage breast cancer.. A similar test became available for colon cancer patients in 2010. The test was originally developed for use in patients with Stage II colon cancer, but has now also ...
Of 3658 patients included, 1813 (49.6%) had lymph nodes removed. Relative survival of patients with lymph node dissection (including those with lymph node metastases) was significantly better than that of patients without, also after correcting for stage, tumour grade, histology and age (89% and 82%, respectively; relative excess risk [RER], 0.64; 95% confidence interval [CI]: 0.52-0.78). There was a positive correlation between the number of removed lymph nodes and overall survival (after excluding patients with lymph node metastases). Of patients with stage I-IIA EOC who had ≥10 lymph nodes removed, there was no difference in relative survival between those who received chemotherapy and those who did not (RER, 0.51; 95% CI: 0.15-1.64). This was also true for a subgroup of patients with high-risk features (stage IC and IIA and/or tumour grade 3 and/or clear cell histology [RER, 0.90; 95% CI: 0.46-1.99 ...
The International Duration Evaluation of Adjuvant chemotherapy (IDEA) collaboration found evidence to support the noninferiority of 3 versus 6 months oxaliplatin-based adjuvant therapy for capecitabine plus oxaliplatin for patients with stage III colon cancer.
Introduction: Endometrial cancer patients with high grade tumours, deep myometrial invasion or advanced stage disease have a poor prognosis. Randomised studies have demonstrated the prevention of loco-regional relapses with radiotherapy (RT) with no effect on overall survival (OS). The possible additive effect of chemotherapy (CT) remains unclear. Two randomised clinical trials (NSGO-EC-9501/EORTC-55991 and MaNGO ILIADE-III) were undertaken to clarify if sequential combination of chemotherapy and radiotherapy improves progression-free survival (PFS) in high-risk endometrial cancer. The two studies were pooled. Methods: Patients (n = 540; 534 evaluable) with operated endometrial cancer International Federation of Obstetrics and Gynaecology (FIGO) stage I-III with no residual tumour andprognostic factors implying high-risk were randomly allocated to adjuvant radiotherapy with or without sequential chemotherapy. Results: In the NSGO/EORTC study, the combined modality treatment was associated with ...
In this pharmacogenetic study, there were significant associations between a common genetic polymorphism in GSTP1 and acute hematologic toxicity but no associations with DFS. Selected polymorphisms in 3 other key genes involved in CP metabolism (CYP2B6 , CYP3A4 , and GSTA1 ) were not associated with hematologic toxicity or DFS following adjuvant therapy. Because CSFs for neutropenia prophylaxis are now commonly used in patients receiving breast cancer adjuvant chemotherapy, our findings of significant associations between the GSTP1 polymorphism and hematologic toxicity suggest that a subgroup of women may be at low risk. Thus, CSF support may not be necessary when considering the cost and potential side effects from growth factors, including bone pain and decreased bone mineral density. However, further confirmation in other data sets using archived specimens, or in a prospective trial, from patients who received CP without CSF support is required before such a strategy would be ...
Management of oesophageal cancer is associated with poor outcomes and it has become apparent that surgery alone is not sufficient to effect genuine long term survival. In the UK, it is standard practice to treat oesophageal adenocarcinoma with neo-adjuvant chemotherapy (no radiation) and surgery. One problem with this approach is the issue of those patients who do not respond. The aim of this study was to investigate biomarkers which might predict response to chemotherapy. Methods A retrospective audit was carried out on post-operative outcome after oesophagectomy from 2000 to 2006 and results compared with those from previous similar audits. Patients who received neo-adjuvant chemotherapy were identified and pre-treatment oesophageal biopsies were obtained. Immunohistochemistry was used to analyse expression ofthymidylate synthase, excision cross-complementation group 1, vascular endothelial growth factor, hypoxia-inducible factor 1 and carbonic anhydrase IX. Expression was compared with ...
Source: Yeo W, Lau TK, Kwok CC, et al. NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin. BMJ Supportive & Palliative Care, 29 January 2020. DOI:10.1136/bmjspcare-2019-002037
Colorectal adenocarcinoma is a major cause of cancer-related morbidity and mortality in Belgium and in other western countries. Prevention implies a modification of alimentation and maybe a chronic uptake of acetylsalicylic acid. Treatment of colorectal cancers is based on surgery and the prognosis is determined by the locoregional or metastatic tumor spread. Complete resection of any Astler Coller stage C colorectal malignant tumor has to be followed by a 5-fluorouracil-based adjuvant chemotherapy. In these protocols, 5-fluorouracil is administered together with folinic acid or levamisole. The administration of an adjuvant chemotherapy could also be considered for stage BII diseases. As rectal cancers are characterized by high local relapse rates, their treatment should associate radiotherapy, given either post-surgery or preferentially pre-surgery, with resection and chemotherapy. Appropriate treatment of colorectal cancers thus requires a concerted multidisciplinary approach.
The decision to treat or not to treat a stage II colon cancer patient with adjuvant chemotherapy remains one of the most challenging areas in colorectal oncology. Currently, up to 40% of stage II patients undergo adjuvant therapy in routine clinical care (34), committing to 6 months of chemotherapy, with the associated risk of potentially serious adverse events and without a method to monitor the impact of adjuvant therapy, for an absolute risk reduction of 3 to 5%. Although multiple clinicopathological markers are now validated and can be combined to define low- and high-risk groups, only a minority of defined high-risk patients will develop recurrence. The benefit of selectively treating these patients with adjuvant therapy also remains to be conclusively proven. Diagnostic approaches that better predict the disease course in this patient population are therefore urgently required.. Here, we have taken a fundamentally different approach to address these issues. We examine postoperative blood ...
Researchers have identified a biomarker that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy.
Aim: Some retrospective studies have shown a lack of benefit of 5-fluorouracil (5-FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer. Our aim was to assess if this molecular marker can predict benefit from 5-FU adjuvant chemotherapy. A second objective was to determine if MMR status influences short term survival.. Methods: We included 754 patients with a median follow up of 728.5 days (range 1-1097). A total of 260 patients with stage II or III tumours received 5-FU adjuvant chemotherapy, according to standard clinical criteria and irrespective of their MMR status. A tumour was considered MMR deficient when either BAT-26 showed instability or there was loss of MLH1 or MSH2 protein expression.. Results: At the end of the follow up period, 206 patients died and 120 presented with tumour recurrence. Sixty six (8.8%) patients had MMR deficient tumours. There were no significant differences in overall survival (MMR competent 72.1%; MMR deficient 78.8%; p = ...
Adjuvant therapy, also known as adjunct therapy, add-on therapy, and adjuvant care, is therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant. An adjuvant agent modifies the effect of another agent, so adjuvant therapy modifies other therapy. Neoadjuvant therapy, in contrast to adjuvant therapy, is given before the main treatment. For example, systemic therapy for breast cancer that is given before removal of a breast is considered neoadjuvant chemotherapy. The most common reason ...
Background: Inflammatory blood markers, such as neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), have been reported as putative prognostic factors for survival and predictive factors for pathological complete response and toxicity in cancers, however with conflicting results. Methods: We retrospectively analyzed data of 280 patients with early breast cancer receiving neo-adjuvant chemotherapy between 2005 and 2013 in our center. Neutrophil count, lymphocyte count and platelet count before treatment were collected as well as data on pathological complete response, toxicity, recurrence and survival. Results: In multivariate analysis, high PLR was an independent prognostic factor for relapse-free survival (hazard ratio [HR] = 1.91; 95%CI = 1.15-3.16; p = 0.012) and for shorter overall survival (HR = 1.83; 95%CI = 1.03-3.24; p = 0.039). NLR was an independent predictive factor for febrile neutropenia (HR = 0.28; 95%CI = 0.13-0.58; p = 0.001). In triple negative breast cancer
Breast cancer patients may experience an increased chance of survival with adjuvant chemotherapy. However dermatologic adverse effects can cause major discomfort due to physical or cosmetic problems. This study aims to describe dermatologic complications in breast cancer patients during chemotherapy.This longitudinal prospective observational study included data on women with non-metastatic breast cancer whom were treated with AC-T protocol (anthracycline, cyclophosphamide, and taxane) adjuvant chemotherapy and consecutively enrolled during two years. The study was performed in an educational and tertiary referral center. The patients information including age, body mass index (BMI), past medical history, and different dermatologic complications were collected for all participants.Of 190 enrolled women, all patients experienced alopecia, which occurred in 131 patients (68.9%) after the first cycle. Skin, mucosal, and nail involvement were respectively seen in 46 (24.2%), 51 (26.8%), and 86 ...
TY - JOUR. T1 - Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer. T2 - A Phase 2 Study. AU - Hardacre, Jeffrey M.. AU - Mulcahy, Mary. AU - Small, William. AU - Talamonti, Mark. AU - Obel, Jennifer. AU - Krishnamurthi, Smitha. AU - Rocha-Lima, Caio S.. AU - Safran, Howard. AU - Lenz, Heinz Joseph. AU - Chiorean, E. Gabriela. PY - 2013. Y1 - 2013. N2 - Background: Despite continued investigation, limited progress has been made in the adjuvant treatment of resected pancreatic cancer. Novel or targeted therapies are needed. Methods: Multi-institutional, open-label, dose-finding, phase 2 trial evaluating the use of algenpantucel-L (NewLink Genetics Corporation, Ames, IA) immunotherapy in addition to chemotherapy and chemoradiotherapy in the adjuvant setting for resected pancreatic cancer (ClinicalTrials. gov identifier, NCT00569387). The primary outcome was 12-month disease-free survival. Secondary outcomes included overall survival and toxicity. Results: ...
by Dr. Mark Lewis, CKN Social Media Editor. Every student of Ethics 101 wrestles with the trolley problem. In this moral exercise of the imagination, you are standing by train tracks watching a runaway trolley race towards 5 people who are going to be crushed unless you intercede. If you pull a lever, the trolley will divert onto a different track, where it is bound to kill one person. In this situation, is it better to be passive or active? Should you pull the lever or not?. While not quite as dramatic a scenario, a similarly freighted decision between inaction and intervention plays out in oncology clinics multiple times every day as doctors weigh the risks & benefits of adjuvant chemotherapy for cancer-free patients.. In this context, the medical oncologist is asking themselves if it is worthwhile to administer potentially toxic treatment when there is no detectable cancer. The quandary arises because, despite confident pronouncements like we got it all! after a patient undergoes an ...
Pathological complete response (pCR) after neoadjuvant (presurgery) chemotherapy was associated with significantly lower recurrence risk and higher overall survival in breast cancer patients, and pCR after neoadjuvant chemotherapy had similar association with improved outcomes among those who received additional chemotherapy following surgery (adjuvant chemotherapy) versus those who did not, according to meta-analyses of data from 52 clinical trials, presented at the 2018 San Antonio Breast Cancer Symposium.
PURPOSE: Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) breast cancer, produces a recurrence score (RS) related to distant disease recurrence (DR) risk (RS%). In node-negative patients, RS can be integrated with clinicopathological parameters to derive RS-pathology-clinical (RSPC) that improves prognostic accuracy. METHODS: Data were collected on patients having clinically indicated tests with an intermediate clinical risk of distant recurrence, and for whom the decision to prescribe chemotherapy remained unclear. Correlation between RS% and RSPC scores was examined. An agreement table was constructed using risk-categorised data. Association between RS%-derived categorical risk assignments and treatment recommendation was evaluated. RESULTS: Data on 171 tests (168 patients) were available. Median DR risk by RS% was 11% (range 3-34%), by RSPC it was 15% (range 4-63%). Correlation ...
In an adjuvant breast cancer trial conducted more than 20 years ago, older patients were randomized to treatment with tamoxifen and prednisone or no adjuvant therapy. Now, at 21 years of follow-up, it is clear that disease-free and overall survival remain better for those who received treatment.
Patients with mental disorders were less likely to be aware of their own breast cancer; the lesions were often found by other people such as family, care staff, and medical staff. Breast cancer patients with mental disorders had significantly more advanced T factors and overall stage at the time of surgery than their counterparts without mental illness, more patients underwent total mastectomy, and fewer patients underwent postoperative adjuvant chemotherapy and radiation. Biological markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression were not significantly different between groups. Disease-free survival and overall survival were not significantly different between groups.. CONCLUSION ...
Adjuvant nivolumab is superior to standard of care ipilimumab in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented ...
Detailed description of various breast cancer treatments is given. An operation to remove the cancer but not the breast itself, includes the various surgical methods. A complete description breast cancer chemotherapy treatment also given.
Another rationale for neoadjuvant systemic therapy is that this allows for the immediate treatment of micrometastases; however, this has not been associated with an increase in survival in most trials to date (Figs. 85-1B and 85-1C). In contrast, a major advantage is that tumor response to chemotherapy is a strong predictor of outcome. Thus neoadjuvant systemic therapy can be used as an in vivo assay of systemic therapy efficacy. This, in theory, can allow for testing of new therapy regimens in the neoadjuvant setting, allowing for shorter and smaller trials to be conducted using chemotherapy response as the primary end point. In addition, the neoadjuvant setting allows the opportunity to identify biomarkers that can predict response as well as identify pharmacodynamic markers of response, that is to say, markers that can change within the primary tumor with the administration of chemotherapy, which can be an early molecular signal of therapy activity. Although the standard of care at this point ...
Chemotherapy is a systemic method of cancer treatment, in contrast with local therapies such as surgery and radiation therapy. The drugs used in chemotherapy are able to reach most parts of the body. Therefore, chemotherapy is likely to be recommended for cancer that has already spread to other areas of the body, for tumors that occur at more than one site, or for tumors that cannot be removed surgically. It is also used when a patient has recurrent disease after initial treatment with surgery or radiation therapy.. Chemotherapy is less mutilating than surgery and helps conserve organ or limb function since anti-cancer drugs are used to act on cancer cells without direct removal of a body part.. For some cancers, chemotherapy alone can destroy all the cancer cells and cure the cancer (primary treatment). As an adjuvant treatment, chemotherapy is given prior to, or after other methods, to increase the effectiveness of cancer treatment. Most often, adjuvant chemotherapy is given after other ...
Inclusion Criteria:. Histologically confirmed solid tumor malignancy for which platinum-based chemotherapy on a 21-day cycle or 14 day cycle is being recommended. Stage I of the trial: newly diagnosed disease for which neoadjuvant or adjuvant chemotherapy is planned in the curative setting, or metastatic disease. Stage II of the trial: evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria must be present for all subjects in the randomized component of the trial- if surgery or radiation is planned, the target lesions may not be so treated until after the assessment of the effect of chemotherapy. Stage I: subjects may have already received no more than 2 cycle of their platinum-based chemotherapy but should not have received other prior chemotherapy regimens with the exception of patients with metastatic disease who received neoadjuvant or adjuvant chemotherapy and that chemotherapy was completed , 6 months prior to enrollment. Stage II: subjects must have received no ...
Introduction. Gene amplification of HER2 occurs in approximately 15% to 25% of breast cancers, resulting in overexpression of HER2 on the cell surface. Before the advent of trastuzumab (Herceptin; H), HER2 amplification was associated with a more aggressive disease course and poorer overall survival.1,2 Prognosis for patients with HER2-positive disease, defined by strong overexpression (3+) of HER2 by immunohistochemistry, or by a HER2 to chromosome 17 copy number ratio of ,2 by fluorescence in situ hybridization, dramatically improved with the advent of HER2-targeted therapy.3 Trastuzumab was approved by the FDA in 1998 in combination with chemotherapy for metastatic HER2-positive breast cancer based on an improvement in overall survival (OS) compared with, chemotherapy alone, and approved in 2006 for use in the adjuvant setting after joint analysis of interim results of National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 and North Central Cancer Treatment Group (NCCTG) 9831 ...
Jay, welcome to our forum; however it would be nicer to meet you under a different set of circumstances. Is your father being treated at a top notch cancer facility by a top notch doctor for colon cancer? This is so very important. Are they going to two prong or three prong the chemo? This means utilizing two or three different types of chemo on a low dosage level. Different chemos work better for certain cancer cells and it is wise to be getting more than one chemo so that no time is wasted on treatment. How old is your father? Has he had surgery? Believe me HOPE is very important to have; so maintain the hope and let me know how things are going. Warmly, lillian We invite you to take a look at our Album. www.angelfire.com/sc/molangels/index.html ( Very informational, good tips, Molers pictures, art work and much more.... ----- Original Message ----- From: ,[email protected], To: ,[email protected], Sent: Monday, December 25, 2000 9:54 PM Subject: Re: [MOL] chemotherapy for Stage III colon ...
mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:\\}.mw-parser-output .citation .cs1-lock-free a{background:url(//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png)no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url(//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png)no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url(//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png)no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output ...
More than 20% of patients with resected stage II colon cancer and 50% of patients with resected stage III colon cancer will develop recurrence. To identify markers for recurrence and to find potentially new targets for treatment, mutations were profiled in tumors from NSABP clinical trial C‐07. TypePLEX chemistry and the Mass Array system from Sequenom (SanDiego CA) were used to profile 238 common, hot‐spot, cancer mutations in 19 genes in 239 colon cancer samples utilizing the OncoCarta panel. Mutations were detected in 7 different genes (ABL1, AKT1, BRAF, KRAS, MET, NRAS and PIK3CA) at 26 different nucleotide positions. Twenty‐four assays which detected mutations in more than 1% of the samples were reconfigured into a new multiplexed panel, termed here as ColoCarta, and used to repeat the profiling of 24 mutant samples. These profiles were identical to those found with OncoCarta, demonstrating reproducibility. The method was also sensitive, requiring as little as 1ng of input DNA. In ...
Background: There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck. Methods: All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed. Results: We ... read more identified a total of 77 patients with an osteosarcoma of the head and neck; the 5-year overall survival (OS) was 55%. In 50 patients with surgically resected high- or intermediate-grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3.78 and 3.66, respectively). Conclusion: In patients younger than 75 years of age with surgically resected high- and intermediate-grade osteosarcoma of the head and neck, treatment with (neo-)adjuvant chemotherapy ...
From July 2003 to April 2011, 302 pts were randomized and 299 (152 CMF, 147 wD) were evaluable. Median age was 71. Hypertension (62%), arthropathy (34%) osteoporosis (17%) and controlled diabetes (16%) were the most frequent comorbidities. At baseline: pT1 44%, pN0 37%, G3 64%, ER+ 75%, HER2+ 19%. After 5.5 years median follow-up, with a plateau of DFS after 108 events (50 with CMF and 58 with wD), the Independent Data Monitoring Committee recommended to anticipate final analysis. HR of DFS for wD vs CMF was 1.20 (95% CI: 0.82-1.75, p = 0.35); HR of death was 1.23 (95% CI: 0.73-2.07, p = 0.42); outcome is similar at multivariable analysis, also including ADL, IADL and Charlson scores. QoL was significantly worse with wD for emesis, appetite loss, diarrhoea, body image, future perspective, side effects and hair loss items. Hematologic toxicity, mucositis and nausea were significantly worse with CMF, while allergy, fatigue, hair loss, onicopathy, dysgeusia, diarrhoea, abdominal pain, neuropathy, ...
Adjuvant chemotherapy Deen, SS; Priest, AN; McLean, MA; Gill, AB; Brodie, C; Crawford, R; Latimer, J; Baldwin, P; Earl, HM; ... Adjuvant and Neoadjuvant Therapy for Breast Cancer (as defined by the US National Institutes of Health (NIH) Valentini, ... chemotherapy, immunotherapy or hormone therapy) or radiation therapy is commonly used in cancers that are locally advanced, and ... "Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer". ...
Hughes, F. A., Higgins, G., & Beebe, G. W. (1966). Present status of surgical adjuvant lung-cancer chemotherapy. JAMA, 196(4), ... Present status of surgical adjuvant lung-cancer chemotherapy. Bronchogenic carcinoma: factors in survival. Linkage of Wartime ...
Falcetta FS, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT, Rosa DD (November 2016). "Adjuvant platinum-based chemotherapy ... "Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer". The Cochrane Database of ... which then usually requires adjuvant radiation therapy), or cisplatin chemotherapy followed by hysterectomy. When cisplatin is ... In addition, chemotherapy can be used to treat cervical cancer, and has been found to be more effective than radiation alone. ...
the cure rate was improved from 10% to 85%. Similarly, the addition of cisplatin to adjuvant chemotherapy led to a marked ... These drugs are used to treat almost half of people receiving chemotherapy for cancer. In this form of chemotherapy, commonly ... "Adjuvant platinum-based chemotherapy for early stage cervical cancer". The Cochrane Database of Systematic Reviews. 11: ... Oun R, Moussa YE, Wheate NJ (2018). "The side effects of platinum-based chemotherapy drugs: a review for chemists". Dalton ...
February 2013). "Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma". The Cochrane Database of ... who were treated with combination chemotherapy including Ifosfamide, were at lower risk of disease progression and death than ...
Adjuvant chemotherapy in older women with early-stage breast cancer. New England Journal of Medicine. 2009;360:2055-2065. Sikov ... Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. New England Journal of Medicine. 2015;372: ... Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients with Node-Positive Breast Cancer. JAMA. 2006;295:1658 ... assessing the use of aspirin as adjuvant therapy for node-positive breast cancer patients. Winer has authored over 250 ...
Sakuramoto (1 November 2007). "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine". NEJM. 357 (18): ... in Japan for most cancers while overall survival tend to be longer in the US due to the more aggressive use of chemotherapy in ... cancer is better in Japan than the US in both patients treated with surgery alone and surgery followed by chemotherapy. Japan ...
They are treated with surgery and adjuvant platinum chemotherapy or radiation. Yolk sac tumors, formerly called endodermal ... Most germ-cell cancers have a better prognosis than other subtypes and are more sensitive to chemotherapy. They are more likely ... Clear-cell ovarian carcinomas do not typically respond well to chemotherapy and may be related to endometriosis. They represent ... Treatment usually includes some combination of surgery, radiation therapy, and chemotherapy. Outcomes depend on the extent of ...
Surgical treatments are typically followed by adjuvant, usually platinum-based, chemotherapy. Radiation therapy has been ... "Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube". Gynecol Oncol. UCSF. "Gynecologic Cancer: ... the patients with advanced stage disease survived 5 years with a surgical approach followed by cisplatinum-based chemotherapy. ...
Higher tumour grades may benefit from adjuvant treatment such as platinum-based chemotherapy. Optimal debulking is used to ... Platinum-based chemotherapy is paramount to treatment of epithelial ovarian cancer. Carboplatin tends to fare better than ... There is a lack of randomized controlled trials comparing outcomes between chemotherapy and optimal debulking, so the current ... Interval debulking surgery may be employed half way through chemotherapy following primary surgery if tumour remains above 1 cm ...
Few studies have shown topical adjuvant chemotherapy to be effective in treating SGc. Neoadjuvant chemotherapy may be used in ... Data on the role of adjuvant radiation therapy in the treatment of SGc is scarce, however, and recurrence following adjuvant ... Postsurgical adjuvant radiation therapy has been used in locally advanced primary tumors and those with positive margins or ... There is a limited amount of information on the effectiveness of chemotherapy for SGc, and it is not indicated for local ...
Packer, R. (1991). "Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma". Journal of ... In 1983 pediatric oncologist Roger Packer began incorporating cisplatin into adjuvant chemotherapy for the treatment of ... Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, ... Cisplatin combination chemotherapy is the cornerstone of treatment of many cancers. Initial platinum responsiveness is high but ...
Mesna - a cancer chemotherapy adjuvant with the same structure Balch WE, Wolfe RS (1979). "Specificity and biological ...
"GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy". J. Transl. Med ...
Chemotherapy also has a role, combined with radiation, in the postoperative setting (adjuvant therapy). Generally it is used ... Concurrent chemotherapy is also superior to chemotherapy alone (induction chemotherapy) followed by radiation. Cetuximab shows ... Consequently, many of these patients have been treated with adjuvant radiation, with or without chemotherapy. In the above ... The addition of chemotherapy to radiation increases acute and late toxicity. In the GORTEC trial, chemotherapy with docetaxel ...
have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. On 16 ... Other adjuvants include proteins or other chemicals that attract and/or activate dendritic cells, such as granulocyte ... The toxic chemicals are those typically used as chemotherapy drugs, but other toxins can be used. The antibody binds to ... Rituximab also increases the sensitivity of cancerous B-cells to chemotherapy. Cytokines are proteins produced by many types of ...
There is evidence to suggest that doxorubicin chemotherapy as an adjuvant can reduce recurrence at the original site or ... 2016(inc details of French system) "Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults". Cochrane ... The use of chemotherapy to prevent the spread of soft-tissue sarcomas has not been proven to be effective. If the cancer has ... Chemotherapy may be used with radiation therapy either before or after surgery to try to shrink the tumor or kill any remaining ...
Adjuvant chemotherapy may also be used post-surgery to prevent further disease spread Heald, R. J.; Husband, E. M.; Ryall, R. D ... Depending on the staging, size and location of the tumour, neoadjuvant radiotherapy often combined with chemotherapy may be ...
Typical chemotherapy is six cycles of intraperitoneally-delivered platinum-base adjuvant chemotherapy with agents such as ... Cytoreductive "debulking" surgery may be performed prior to chemotherapy treatment in order to decrease the physical mass of ... although it is more sensitive to platinum-based chemotherapy, possibly due to its rapid growth rate. In rare cases, HGSCs can ... "Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum". Gynecologic Oncology. 108 (3): 510-514. ...
The best outcomes occur when total resection of the tumor is combined with adjuvant chemotherapy and radiotherapy. In the event ... Possible interventions include inserting shunts, surgical resection, radiotherapy, and chemotherapy. Inserting a shunt could ...
There is no proven benefit to adjuvant chemotherapy or supplementing other treatments for this kind of tumor. Although ... temozolomide is effective for treating recurrent anaplastic astrocytoma, its role as an adjuvant to radiation therapy has not ...
... (ethiofos) is a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding ...
"Mycobacterium vaccae as Adjuvant Therapy to Anti-Tuberculosis Chemotherapy in Never-Treated Tuberculosis Patients: A Meta- ... in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small- ...
Adjuvant chemotherapy for localised resectable soft tissue sarcoma of adults: A meta-analysis of individual patient data. ... High-dose chemotherapy for breast cancer. JAMA 1999;282:1701-1703. Antman K and Y Chang, Kaposi's Sarcoma. New England Journal ... Zalupski MM, Rankin C, Ryan JR, Lucas DR, Muler J, Lanier KS, Budd GT, Biermann JS, Meyers FJ, Antman K. Adjuvant therapy of ... Antman developed standards for the treatment of patients receiving chemotherapy including pharmacology, growth factors and ...
... including the increased use in adjuvant chemotherapy. The National Institute of Health (NIH) attributes the increase in the 5- ... Where surgery was previously the only option for treatment, cancer is now treated with radiation and chemotherapy, including ... "Evolution of Cancer Treatments: Chemotherapy". American Cancer Society. "Search of: cancer - List Results - ClinicalTrials.gov ... combination chemotherapy that favors treatment with many drugs over just one. Availability and access to clinical trials has ...
A study of the usefulness of platinum-based chemotherapy as an adjuvant after surgery of stage I patients showed that patients ... treated with adjuvant platinum-based chemotherapy". Gynecol Oncol. 98 (3): 353-9. doi:10.1016/j.ygyno.2005.06.012. PMID ... patients with stage 1B disease with chemotherapy had no recurrence, while those without chemotherapy had a high degree (77%) of ... In a study to determine if adjuvant therapy should be used in patients with stage I UPSC who had undergone surgery, no ...
For malignant tumours, the surgery may be radical and usually is followed by adjuvant chemotherapy, sometimes by radiation ... Immunohistochemical markers of Leydig cell tumours include inhibin-alpha, calretinin, and melan-A. The usual chemotherapy ...
Vincristine, Adriamycin, and bleomycin are used for adjuvant chemotherapy, but their effects are not good enough according to ...
It has not been demonstrated that adjuvant treatment (chemotherapy or radiation therapy) improves the survival rate for ... For this reason, there are no current indications for the use of chemotherapy or hormone therapy even in advanced cases. The ... The importance of correct surgical staging lies in the need for a change in surgical treatment and postoperative adjuvant ... for which cases the chemotherapy regimen used is the same as that for invasive carcinoma (consisting of a platinum-containing ...
327-337 Porter A.B., Bernold D.M., Giannini C., et al: Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma ... then for radiotherapy and chemotherapy (51%), just surgery (48%), surgery, radiotherapy and chemotherapy (47%) and finally just ... Chemotherapy is used in a multimodality treatment plan generally for more advanced, unresectable or reoccurring tumors. ... More progressed, higher grade tumors would result in chemotherapy or radiotherapy as the only treatment. It is no surprise that ...
... adjuvant - administration - Adult AIDS Clinical Trials Group (AACTG) - adverse drug reaction - aerosolized - AETC - ... chemotherapy - Chlamydia - chronic idiopathic demyelinating polyneuropathy (CIPD) - Circumoral paresthesia - clade - clinical ...
Adjuvant chemotherapy and radiation therapyEdit. If the tumor can be removed surgically, people may receive adjuvant ... Adjuvant chemotherapy appears to be ineffective in people with completely resected tumors.[75] The role of combined ... then adjuvant therapy with radiation and possibly chemotherapy is generally recommended based on the available data.[76] ... "Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized ...
... is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible ... Preventive (adjuvant) doses are typically around 45-60 Gy in 1.8-2 Gy fractions (for breast, head, and neck cancers.) Many ... It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor ... This is most commonly seen in the treatment of breast cancer with wide local excision or mastectomy followed by adjuvant ...
Active surveillance, surgery, radiation therapy, hormone therapy, chemotherapy[2]. Prognosis. 5-year survival rate 99% (US)[4] ... "Expression of X-linked inhibitor of apoptosis protein in human prostate cancer specimens with and without neo-adjuvant hormonal ... Systemic chemotherapy for prostate cancer was first studied in the 1970s. The initial regimen of cyclophosphamide and 5- ... Cryotherapy (the process of freezing the tumor), hormonal therapy, and chemotherapy may also be offered if initial treatment ...
... osteoporosis and as adjuvant therapy during cancer chemotherapy. ...
Adjuvant analgesics, also called atypical analgesics, include nefopam, orphenadrine, pregabalin, gabapentin, cyclobenzaprine, ... Refractory chemotherapy-induced nausea and vomiting; anorexia; neuropathic pain.. Dizziness, euphoria, paranoia, somnolence, ... The use of adjuvant analgesics is an important and growing part of the pain-control field and new discoveries are made ... Main article: analgesic adjuvant. Drugs that have been introduced for uses other than analgesics are also used in pain ...
... neoadjuvant chemotherapy) and post-operatively (adjuvant chemotherapy). ... "Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer". The Cochrane ... Certain people that are deemed to be higher risk may also receive adjuvant (ancillary) chemotherapy after initial surgery or ... however a wide variety of chemotherapy options exist.[41][42] These agents include both traditional chemotherapies like ...
Adjuvant chemotherapy is given after a local treatment (radiotherapy or surgery). It can be used when there is little evidence ... Intensification chemotherapy is identical to consolidation chemotherapy but a different drug than the induction chemotherapy is ... Chemotherapy. A woman being treated with docetaxel chemotherapy for breast cancer. Cold mittens and wine coolers are placed on ... The term chemotherapy[edit]. The word chemotherapy without a modifier usually refers to cancer treatment, but its historical ...
Vinblastine and CCNU are common chemotherapy agents used to treat mast cell tumors. Toceranib and masitinib, examples of ... factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant ... such as radiation therapy or chemotherapy, may be necessary. Prednisone is often used to shrink the remaining tumor portion. H2 ...
Chemotherapy. Chemotherapy is the treatment of cancer with one or more cytotoxic anti-neoplastic drugs (chemotherapeutic agents ... Bagri A, Kouros-Mehr H, Leong KG, Plowman GD (March 2010). "Use of anti-VEGF adjuvant therapy in cancer: challenges and ... The efficacy of chemotherapy depends on the type of cancer and the stage. In combination with surgery, chemotherapy has proven ... The effectiveness of chemotherapy is often limited by its toxicity to other tissues in the body. Even when chemotherapy does ...
Do not randomize antigen plus adjuvant versus adjuvant alone. The goal is to establish clinical benefit of the immunotherapy (i ... One alternative is to target patients with residual disease after surgery, radiotherapy or chemotherapy that does not harm the ... The adjuvant may have a low-level clinical effect that skews the trial, increasing the chances of a false negative. ... Selection of the appropriate adjuvant to activate antigen-presenting cells to stimulate immune responses, is required. Bacillus ...
99,0 99,1 «The introduction of 'chemotherapy' using arsphenamine - the first magic bullet»։ Journal of the Royal Society of ... 143,0 143,1 143,2 143,3 «Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens»։ Chemical Biology ... 144,0 144,1 «Bacteriophage therapy»։ Antimicrobial Agents and Chemotherapy 45 (3): 649-59։ March 2001։ PMC 90351։ PMID 11181338 ... 80,0 80,1 «The growing burden of antimicrobial resistance»։ The Journal of Antimicrobial Chemotherapy։ 62 Suppl 1 (Supplement 1 ...
Lind M.J. M.J. (2008)։ «Principles of cytotoxic chemotherapy»։ Medicine 36 (1): 19-23։ doi:10.1016/j.mpmed.2007.10.003 ... Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale»։ Trends in Molecular Medicine 16 (3): 122-32։ March 2010 ... The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy»։ Journal of Neurology, ... 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage ...
Adjuvant chemotherapy refers to the use of chemotherapy after apparently curative surgery to improve the outcome. In NSCLC, ... Chemotherapy[edit]. The chemotherapy regimen depends on the tumor type.[6] Small-cell lung carcinoma (SCLC), even relatively ... If stage II or III disease is confirmed, adjuvant chemotherapy (including or not including postoperative radiotherapy) improves ... Chemotherapy may be combined with palliative care in the treatment of the NSCLC. In advanced cases, appropriate chemotherapy ...
He J, Shen J, Yang C, Jiang L, Liang W, Shi X, Xu X, He J. Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall ... Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. The Cochrane Database of Systematic Reviews. March ... 辅助化疗(英语:Adjuvant therapy)是指在進行根除型手术後再实施化疗,目的是提高疗效。对于非小细胞肺癌,手术过程中会在病灶旁淋巴结取样以辅助分期。如果确定其为肺癌II或III期
"Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I ... Most previous chemotherapy drugs for cancer were (relatively) nonselective in their activity. Although their exact mechanisms ... Additionally, SCLC's are typically much more sensitive to chemotherapy and/or radiation therapy than are NSCLC's. Therefore, ... and chemotherapy with or without radiotherapy for SCLC.[6][7] ... compared with etoposide plus carboplatin in chemotherapy-naive ...
Just as for chemotherapy, radiotherapy can be used in the neoadjuvant and adjuvant setting for some stages of rectal cancer. ... ChemotherapyEdit. In both cancer of the colon and rectum, chemotherapy may be used in addition to surgery in certain cases. The ... In Stage I colon cancer, no chemotherapy is offered, and surgery is the definitive treatment. The role of chemotherapy in Stage ... Typically in this setting, a number of different chemotherapy medications may be used.[19] Chemotherapy drugs for this ...
Adjuvant capecitabine plus oxaiplatin for gastric cancer after D2 gastrectomy CLASSIC: 5 zear follow-up of an open label, ... Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. ...
De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive ... Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy ... Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma PMID 17054200 https://doi.org/10.1002/ ... Done Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer PMID 19588382 https://doi. ...
Singh M, O'Hagan D (1999). "Advances in vaccine adjuvants". Nat Biotechnol. 17 (11): 1075-81. PMID 10545912.. ... "Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy". Immunity. 44 (2): 343-354. doi:10.1016/j.immuni. ... "Breakdown of pulmonary host defense in the immunocompromised host: cancer chemotherapy". Proc Am Thorac Soc. 2 (5): 445-8. ... "Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from ...
2007). „The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer". Journal of Thoracic Oncology. 2 (5): ... Le Chevalier, T (2010). „Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?". Annals of ... Wakelee, HA; Schiller JH; Gandara DR (2006). „Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: ... 1977). „Intensive chemotherapy of small cell bronchogenic carcinoma". Cancer Treatment Reports. 61 (3): 349-354. PMID 194691.. ...
people with a tumor larger than 5 cm (2 inches) that doesn't shrink very much with neoadjuvant chemotherapy ... the availability of adjuvant radiation, and the willingness of the patient to accept higher rates of tumor recurrences after ... an analysis of surgical techniques used in an international trial of adjuvant treatment among 4,700 females with early breast ... this time the doctor will explain the results and talk about further treatment if needed such as radiation and chemotherapy. ...
Vehmanen L, Elomaa I, Blomqvist C, Saarto T (February 2006). "Tamoxifen treatment after adjuvant chemotherapy has opposite ... Bruce A. Chabner; Dan L. Longo (7 December 2011). Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott ... Nagar S (2010). "Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy". Advances in Experimental Medicine ... 1980 saw the publication of the first trial to show that tamoxifen given in addition to chemotherapy improved survival for ...
Adjuvant use was safe and effective in 3 trials for cancer pain, however the drug failed to meet its primary endpoint for this ... crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced ...
"Adjuvant breast disease: an evaluation of 100 symptomatic women with breast implants or silicone fluid injections." The Keio ... treated successfully by simple removal of the implant and the capsule surrounding the implant without the need for chemotherapy ... especially in women who received adjuvant external radiation therapy.[55] Moreover, besides breast reconstruction, breast ...
... (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of ... Many more side effects have been reported for conjunctive and adjuvant treatment with docetaxel as well as rare post-marketing ... Docetaxel is a cytotoxic chemotherapeutic agent.[9][22] As with all chemotherapy, adverse effects are common, and many side ... Koren G, Carey N, Gagnon R, Maxwell C, Nulman I, Senikas V (March 2013). "Cancer chemotherapy and pregnancy". J Obstet Gynaecol ...
Chemotherapy[edit]. After surgery, adjuvant chemotherapy with gemcitabine or 5-FU can be offered if the person is sufficiently ... This was the first chemotherapy drug approved by the FDA primarily for a nonsurvival clinical trial endpoint.[75] Chemotherapy ... Chemotherapy and, to a lesser extent, radiotherapy are likely to be offered to most people, whether or not surgery is possible ... Tejani MA, Saif MW (2014). "Pancreatic neuroendocrine tumors: Does chemotherapy work?". Journal of the Pancreas. 15 (2): 132-4 ...
... alpha lipoic acid and n-acetyl cysteine as anti-CIPN adjuvants concluded that "currently no agent has shown solid beneficial ... of patients undergoing chemotherapy. Chemotherapy drugs associated with CIPN include thalidomide, the epothilones such as ... Chemotherapy-induced Peripheral Neuropathy. NCI Cancer Bulletin. Feb 23, 2010;7(4):6. Grisold W, Oberndorfer S, Windebank AJ. ... Savage L. Chemotherapy-induced pain puzzles scientists. Journal of the National Cancer Institute. 2007;99(14):1070-1071. doi: ...
Antibiotic adjuvant[edit]. While HAMLET on its own is not active against most bacteria, when present together with antibiotics ... History of cancer chemotherapy. *Experimental cancer treatment. References[edit]. *^ a b c d Ho C S, J; Rydström, A; Trulsson, ...
A 2013 review and metaanalysis of randomised controlled trials of acupuncture as an adjuvant therapy in IVF found no overall ... These are resources for women with no eggs due to surgery, chemotherapy, or genetic causes; or with poor egg quality, ... oocyte cryopreservation can be used for women who are likely to lose their ovarian reserve due to undergoing chemotherapy.[72] ...
Chemotherapy: Adjuvant chemotherapy is the use of drugs to eradicate or suppress residual disease after surgery or irradiation ... Adjuvant chemotherapy reduces the rate of recurrence of… ... In therapeutics: Chemotherapy. Adjuvant chemotherapy is the use ... Other articles where Adjuvant chemotherapy is discussed: therapeutics: ...
... Paul H. Sugarbaker and Lana Bijelic ... I. Vergote, F. Amant, K. Leunen et al., "Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view," ... E. L. Trimble, S. Thompson, M. C. Christian, and L. Minasian, "Intraperitoneal chemotherapy for women with epithelial ovarian ... P. Jacquet and P. H. Sugarbaker, "Effects of postoperative intraperitoneal chemotherapy on peritoneal wound healing and ...
Pancreatic cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Evidence-based medicine Transcriptomics Precision medicine ... Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120(8):899-903CrossRefGoogle Scholar ... Adjuvant chemotherapy with gemcitabine and capecitabine in unselected patients can double 5-year overall survival to around 30 ... The aim of this article was to summarize existing evidence on neoadjuvant and adjuvant chemotherapy in PDAC with a focus on ...
Psychiatric morbidity and physical toxicity associated with adjuvant chemotherapy after mastectomy. Br Med J 1980; 281 :1179 ... Psychiatric morbidity and physical toxicity associated with adjuvant chemotherapy after mastectomy.. Br Med J 1980; 281 doi: ...
Connected Prehabilitation Program During Neo Adjuvant Chemotherapy (TRAINING). The safety and scientific validity of this study ... Patient with neo adjuvant chemotherapy (min 3 cycles, max 6 cycles),. *Capability to perform a cardiopulmonary exercise test ( ... Connected Prehabilitation Program During Neo Adjuvant Chemotherapy Official Title ICMJE Multicenter Randomized Study Comparing ... Neo Adjuvant Chemotherapy for Patients Managed for Ovarian Cancer With or Without a Connected Prehabilitation Program ...
J. A. Broeckel, P. B. Jacobsen, L. Balducci, J. Horton, and G. H. Lyman, "Quality of life after adjuvant chemotherapy for ... Psychoneuroimmunology-Based Stress Management during Adjuvant Chemotherapy for Early Breast Cancer. Jo Lynne W. Robins,1 Nancy ... In a randomized trial of women with early stage breast cancer undergoing adjuvant chemotherapy, two stress management ... in comparison to a usual care control group among women receiving adjuvant chemotherapy for stages I-IIIA breast cancer. We ...
... developed evidence-based recommendations for adjuvant chemotherapy for stage II colon cancer. This guide for patients is based ... Adjuvant Chemotherapy for Stage II Colon Cancer. August 16, 2004. To help doctors give their patients the best possible care, ... Adjuvant chemotherapy for stage II colon cancer may lower the risk of the cancer coming back, but is also associated with ... Adjuvant therapy is additional treatment given after surgery to reduce the risk that the cancer will come back. Chemotherapy is ...
... information on adjuvant chemotherapy but do not address which patients can be spared unnecessary adjuvant chemotherapy. He ... either adjuvant chemotherapy immediately after surgery for early-stage ovarian cancer or no immediate adjuvant chemotherapy. ( ... observed benefit of adjuvant chemotherapy primarily in nonoptimally staged patients suggests a benefit of adjuvant chemotherapy ... optimal staging was not associated with any survival benefit in patients who received adjuvant chemotherapy. Adjuvant ...
NAC Sparing Mastectomy After Neo-adjuvant Chemotherapy. The safety and scientific validity of this study is the responsibility ... Nipple Areolar-complex Sparing Mastectomy After Neo-adjuvant Chemotherapy: Evaluation of Local Oncologic Safety in a Cohort ... with or without treatment with neo-adjuvant chemotherapy, the selection of patients for NAC-sparing mastectomy has been made on ... one with tumor size after neoadjuvant chemotherapy and one with tumor size before neoadjuvant chemotherapy as balancing ...
Connected Prehabilitation Program During Neo Adjuvant Chemotherapy (TRAINING). The safety and scientific validity of this study ... Patient with neo adjuvant chemotherapy (min 3 cycles, max 6 cycles),. *Capability to perform a cardiopulmonary exercise test ( ... Multicenter Randomized Study Comparing Neo Adjuvant Chemotherapy for Patients Managed for Ovarian Cancer With or Without a ...
Adjuvant chemotherapy is given after surgery for early stage cancer. It aims to cure. Though potentially toxic, it has ... Adjuvant chemotherapy is given after surgery for early stage cancer. It aims to cure. Though potentially toxic, it has ... But as I lived the ordeal of adjuvant chemotherapy, I felt a growing urge to capture that experience as data and subject it to ... In sum, the lived-body strangeness of adjuvant chemotherapy is aptly captured in Staceys notion of the abject. But in my own ...
Experimental: ARM A Durvalumab/chemotherapy association Drug: ARM A Durvalumab/chemotherapy association NEO-ADJUVANT Cycle 1 : ... Cycle 1 : chemotherapy alone (day1) Cycle 2 : chemotherapy + durvalumab (day1) Cycle 3 : chemotherapy + durvalumab (day1) ... Cycle 1 : chemotherapy alone (day1) Cycle 2 : chemotherapy + durvalumab + tremelimumab (day1) Cycle 3 : chemotherapy + ... Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (INeOV). The safety and scientific validity of this study is ...
One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women ... Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/ ... Conclusions: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival ... breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy. ...
... that means you will be receiving both chemotherapy and surgery. Learn more... ... If your cancer treatment plan includes adjuvant or neoadjuvant chemotherapy, ... When are Neoadjuvant Chemotherapy and Adjuvant Chemotherapy Used?. Adjuvant chemotherapy and neoadjuvant chemotherapy are ... Side Effects of Adjuvant and Neoadjuvant Chemotherapies. The side effects of adjuvant and neoadjuvant chemotherapy are the same ...
Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer.. Bastarrachea J1, ... To determine whether obesity is an independent prognostic factor among women receiving adjuvant chemotherapy for lymph node- ... an indicator of poor prognosis for patients with primary breast cancer even after the administration of adjuvant chemotherapy. ... with stages II and III primary breast cancer who were treated using three consecutive postoperative adjuvant chemotherapy ...
... phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with ... CONCLUSION: Our observations indicate that MSI status and p53 expression may influence the impact of oxaliplatin on adjuvant ... A Cox proportional hazards model was specifically designed to evaluate the interaction between chemotherapy and these genetic ... while the interaction of MSI with chemotherapy could not be determined in the absence of relapse in the MSI group treated with ...
PURPOSE: Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time ... Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. ... PATIENTS AND METHODS: A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant ... CONCLUSIONS: These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with ...
Adjuvant" by people in Harvard Catalyst Profiles by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of ... Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. ... Peng C, Ho J, Bai HX, Huang Y, Huang RY, Yang L. Adjuvant radiotherapy and chemotherapy in early-stage diffuse large B cell ... "Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ...
... known as adjuvant chemotherapy, may not be benefiting from these drugs. ... "Adjuvant chemotherapy is a well established, but ineffective treatment in ER+ breast cancer patients aged 40 years or less . ... Article: Efficacy of adjuvant chemotherapy according to hormone receptor status in young breast cancer patients, Jos A. van ... known as adjuvant chemotherapy, may not be benefiting from these drugs. This is especially true if their tumors respond to ...
Forty-five breast cancer patients, eligible for adjuvant C … ... It is an open question if chemotherapy (CT) per se imposes ... of the present study was to investigate effects of CT on salivary function in breast cancer patients during and after adjuvant ... Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction Oral Oncol. 2008 Feb;44(2):162-73 ... It is an open question if chemotherapy (CT) per se imposes adverse effects on salivary gland function. The aim of the present ...
Chemotherapy, Adjuvant. Cisplatin / adverse effects, therapeutic use. Diarrhea / chemically induced, etiology. Dose ... Ten days after radiation therapy, TP regimen was administered as adjuvant chemotherapy.. RESULTS: For the experimental and ... CONCLUSION: Concurrent chemoradiotherapy plus adjuvant chemotherapy for advanced cervical cancer can improve short-term and ... This study aimed to explore the efficacy of concurrent chemoradiotherapy plus adjuvant chemotherapy on and the treatment ...
IIIA non-small-cell lung cancer includes adjuvant chemotherapy based on the results of randomized trials using cisplatin ... A recent meta-analysis (Lung Adjuvant Cisplatin Evaluation) showed no surv ... However, long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in ... Chemotherapy, Adjuvant / methods. Cisplatin / administration & dosage. Humans. Lung Neoplasms / drug therapy*, pathology. ...
We conducted a retrospective review of data from 106 patients who had received adjuvant chemotherapy. The adjuvant chemotherapy ... The PNI before adjuvant chemotherapy influenced the treatment compliance with the planned chemotherapy in the OT group, but not ... it is important to identify risk factors for the continuation of adjuvant chemotherapy. In this study, we analyzed chemotherapy ... The RFS of patients with a PNI ,50 before adjuvant chemotherapy was significantly poorer than that of the patients with a PNI ≥ ...
NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma.. [David W Cescon, Desmond She, ... However, improved survival with adjuvant chemotherapy in the JBR.10-randomized trial appears limited to patients with the WT ... the clinical relevance of these findings and assessed whether NRF2 activation predicts benefit from adjuvant chemotherapy in ... A gene expression signature of NRF2 pathway activation is associated with benefit from adjuvant cisplatin/vinorelbine in SCC. ...
Cancer & chemotherapy 2004-1-31 [Appropriate duration of postoperative oral adjuvant chemotherapy with HCFU for colorectal ... We conducted a joint study of different duration of drug administration for oral adjuvant chemotherapy using camphor (HCFU) ... It appears that oral adjuvant chemotherapy with HCFU is more effective when administered for 2 years than for 6 months. ...
IntroductionPolymer-based delivery systems offer innovative intra-cavity administration of drugs, with the potential to better target micro-deposits of cancer cells in brain parenchyma beyond the resected cavity. Here we evaluate clinical utility, toxicity and sustained drug release capability of a novel formulation of poly(lactic-co-glycolic acid) (PLGA)/poly(ethylene glycol) (PEG) microparticles. MethodsPLGA/PEG microparticle-based matrices were molded around an ex vivo brain pseudo-resection cavity and analyzed using magnetic resonance imaging and computerized tomography. In vitro toxicity of the polymer was assessed using tumor and endothelial cells and drug release from trichostatin A-, etoposide- and methotrexate-loaded matrices was determined. To verify activity of released agents, tumor cells were seeded onto drug-loaded matrices and viability assessed. ResultsPLGA/PEG matrices can be molded around a pseudo-resection cavity wall with no ...
What is adjuvant chemotherapy? Learn about this cancer treatment, including who may be a candidate and what to expect from the ... Adjuvant chemotherapy for breast cancer. Adjuvant chemotherapy is commonly used for breast cancer when:. *Cells have migrated ... What is adjuvant chemotherapy?. Adjuvant chemotherapy is a cancer treatment that combines different healing therapies to ... What types of cancer is adjuvant chemotherapy used for?. Adjuvant chemotherapy is mainly used for cancers in the following body ...
The present study explored the beneficial effects of AHCC on adverse events in patients receiving adjuvant chemotherapy for ... Effect of active hexose-correlated compound in women receiving adjuvant chemotherapy for breast cancer: a retrospective study. ... Effect of Active Hexose-Correlated Compound in Women Receiving Adjuvant Chemotherapy for Breast Cancer: A Retrospective Study ... AHCC has the potential to reduce the severity of neutropenia induced by breast cancer chemotherapy and the use of G-CSF during ...
... before resection of the primary tumotm to adjuvant HIPEC followed by routine adjuvant systemic chemotherapy (experimental group ... and intention to start adjuvant systemic chemotherapy. Patients with metastatic disease were ineligible. Adjuvant HIPEC ... Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, ... We aimed to determine the efficacy of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally ...
... based chemotherapy after surgery can be given safely to selected elderly patients with stage II/III colon cancer, and these ... adjuvant chemo-therapy. Data from the National Cancer Institutes. Surveillance Epidemiology, and End Results Program (SEER) ... regimens after surgery with no adjuvant chemotherapy for patients with stage. II/III colon cancer. Five studies used 5-FU plus ... Reasons for withholding adjuvant chemotherapy from elderly patients may. include coexisting conditions, fear of toxicity, ...
  • Following upfront resection, adjuvant chemotherapy has become mandatory to prevent early tumor recurrence. (springer.com)
  • Results from two large European studies suggest that adjuvant chemotherapy immediately after surgery for early-stage ovarian cancer can increase some patients chances of both overall and recurrence-free survival. (innovations-report.com)
  • However, recurrence-free survival was statistically significantly improved, with 76% of patients treated with adjuvant chemotherapy surviving without a recurrence, compared with 68% of patients in the observation arm. (innovations-report.com)
  • Moreover, the authors found that among patients who did not receive adjuvant chemotherapy, optimal staging was associated with a statistically significant improvement in overall and recurrence-free survival. (innovations-report.com)
  • At 5 years, women who received adjuvant chemotherapy had a 9% greater overall survival and an 11% greater recurrence-free survival than women who did not receive immediate adjuvant therapy. (innovations-report.com)
  • The analysis also found that 5-year recurrence-free survival was 11% better in the adjuvant chemotherapy arm than in the observation arm. (innovations-report.com)
  • Adjuvant chemotherapy is administered after surgery to kill any remaining cancer cells with the goal of reducing the chances of recurrence. (rockymountaincancercenters.com)
  • Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. (uptodate.com)
  • PURPOSE: Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. (uptodate.com)
  • PATIENTS AND METHODS: A total of 12,233 patients enrolled to the randomized trials C-07, C-08, N0147, MOSAIC (Adjuvant Treatment of Colon Cancer), and XELOXA (Adjuvant XELOX) were pooled to examine the impact of oxaliplatin and tumor-specific factors on the time course of recurrence and death. (uptodate.com)
  • Adjuvant chemotherapy reduces the risk of a recurrence in high-risk patients. (mercy.com)
  • When successful, adjuvant chemotherapy reduces the risk of breast cancer recurrence by 35 percent for women under 50 and by 20 percent in women over 50 years old. (mercy.com)
  • Adjuvant chemotherapy given to patients following underwent radical surgery for locally advanced upper tract urothelial carcinoma was associated with a significantly decreased risk of tumor recurrence. (renalandurologynews.com)
  • Adjuvant chemotherapy (AC) improves recurrence-free survival in patients with locally advanced upper tract urothelial carcinoma (UTUC), according to a new study. (renalandurologynews.com)
  • Chemotherapy after surgery, known as adjuvant chemotherapy, led to higher rates of disease-free and overall survival for women with isolated local or regional recurrence of breast cancer. (oncologynurseadvisor.com)
  • Aebi recommended that physicians prescribe adjuvant chemotherapy for patients with isolated local and regional recurrence of breast cancer, especially if the recurrence is ER-negative and therefore not sensitive to endocrine therapy. (oncologynurseadvisor.com)
  • These results indicate that cisplatin is most promising for the partner of S-1 as adjuvant therapy that may reduce recurrence and improve survival of stage III gastric cancer. (ovid.com)
  • however, interviews showed that there was evidence of a lack of understanding of key information among some patients, in particular their baseline risk of recurrence, the net benefit of combination chemotherapy and the rationale for having chemotherapy when cancer had apparently gone. (bmj.com)
  • Suggested improvements for the DA include: sequential presentation of treatment options (eg, no treatment vs 1 drug, 1 drug vs 2 drugs) to enhance patient understanding of the difference between combination and single therapy, diagrams to help patients understand the rationale for chemotherapy to prevent a recurrence and inbuilt checks on patient understanding of baseline risk of recurrence and net benefit of chemotherapy. (bmj.com)
  • Neoadjuvant chemotherapy was associated with a higher local recurrence rate in patients with early breast cancer. (ascopost.com)
  • A meta-analysis reported in The Lancet Oncology by the Early Breast Cancer Trialists' Collaborative Group indicates that neoadjuvant chemotherapy is associated with a higher local recurrence risk vs the same chemotherapy given postoperatively after breast-conserving therapy. (ascopost.com)
  • Local recurrence rates at 15 years were 21.4% for neoadjuvant chemotherapy vs 15.9% for adjuvant chemotherapy (rate ratio [RR] = 1.37, P = .0001). (ascopost.com)
  • There were no significant differences between neoadjuvant chemotherapy and adjuvant therapy for 15-year distant recurrence (38.2% vs 38.0%, RR = 1.02, P = .66), breast cancer mortality (34.4% vs 33.7%, RR = 1.06, P = .31), or all-cause mortality (40.9% vs 41.2%, RR = 1.04, P = .45). (ascopost.com)
  • The investigators concluded: "Tumours downsized by [neoadjuvant chemotherapy] might have higher local recurrence after breast-conserving therapy than might tumours of the same dimensions in women who have not received [neoadjuvant chemotherapy]. (ascopost.com)
  • Strategies to mitigate the increased local recurrence after breast-conserving therapy in tumours downsized by [neoadjuvant chemotherapy] should be considered-e.g., careful tumour localisation, detailed pathological assessment, and appropriate radiotherapy. (ascopost.com)
  • Due to this pattern, the addition of radiotherapy appears as a logical adjuvant treatment aiming to decrease loco-regional recurrence and improve survival. (biomedcentral.com)
  • Because taxanes exhibit incomplete cross-resistance with anthracyclines, and adjuvant anthracycline chemotherapy still leaves considerable residual risk of disease recurrence and death from breast cancer, multiple trials are addressing the value of incorporating taxanes, either sequentially or in combination with anthracyclines, in an effort to improve outcomes ( 8 , 9 ). (aacrjournals.org)
  • Recurrence, survival, and quality of life (QOL) is not improved with adjuvant chemotherapy in most patients with stage II colon cancer, according to the results of a study published in Supportive Care in Cancer . (oncologynurseadvisor.com)
  • In addition, significantly higher odds of cancer recurrence were seen among those patients who received chemotherapy. (oncologynurseadvisor.com)
  • In this study, stage II colon cancer patients who received chemotherapy treatment were more likely to have poor QoL, recurrence, and all-cause mortality after 24 months compared to those who did not receive chemotherapy. (oncologynurseadvisor.com)
  • Moreover, although the host immune function of breast cancer patients on chemotherapy affects the recurrence rate ( 12 ), anthracycline-based chemotherapy is reported to adversely affect immune function ( 13 ). (spandidos-publications.com)
  • Secondary endpoints are postoperative cholangitis, time to recurrence or distant metastasis, changes in nutritional index, changes in the lymphocyte blast transformation test induced by phytohaemagglutinin, and concanavalin A and diamine oxidase serum activity during adjuvant chemotherapy. (bmj.com)
  • Neuropathy is a common complication that could result in chemotherapy dose reduction, but there is no evidence that this toxicity is associated with a higher risk of recurrence or inferior survival (6). (deepdyve.com)
  • Peng C, Ho J, Bai HX, Huang Y, Huang RY, Yang L. Adjuvant radiotherapy and chemotherapy in early-stage diffuse large B cell lymphoma of head and neck with extranodal involvement. (harvard.edu)
  • Women under the age of forty with breast cancer who are given drugs in addition to lumpectomies or radiotherapy, known as adjuvant chemotherapy, may not be benefiting from these drugs. (science20.com)
  • Adjuvant radiotherapy improves lymph node-field control in patients at high risk of relapse after therapeutic lymphadenectomy for metastatic melanoma, an Australian-New Zealand study has confirmed. (amazonaws.com)
  • Following completion of chemotherapy, patients who underwent breast conservation surgery receive radiotherapy. (knowcancer.com)
  • Two randomised clinical trials (NSGO-EC-9501/EORTC-55991 and MaNGO ILIADE-III) were undertaken to clarify if sequential combination of chemotherapy and radiotherapy improves progression-free survival (PFS) in high-risk endometrial cancer. (diva-portal.org)
  • 534 evaluable) with operated endometrial cancer International Federation of Obstetrics and Gynaecology (FIGO) stage I-III with no residual tumour andprognostic factors implying high-risk were randomly allocated to adjuvant radiotherapy with or without sequential chemotherapy. (diva-portal.org)
  • A remaining question for future studies is if addition of radiotherapy to chemotherapy improves the results. (diva-portal.org)
  • Patients with primary, high-grade soft tissue sarcoma of the extremities will undergo treatment of their primary tumor with either amputation or limb-sparing surgery and radiotherapy, and then be randomized to either observation or adjuvant treatment with doxorubicin and ifosfamide with mesna (with G-CSF) for five cycles beginning post-operatively. (bioportfolio.com)
  • The purpose of the present study is to assess the feasibility and the potential impact of adjuvant radiotherapy (RT) in a series of patients treated in one institution. (biomedcentral.com)
  • We agree with Krzysztof and Magdalena Bujko that a meta-analysis of individual patients' data is needed to resolve whether adjuvant chemotherapy produces worthwhile benefits in patients with rectal cancer who receive preoperative or postoperative radiotherapy. (warwick.ac.uk)
  • The QUASAR study does, however, provide no reason to believe that chemotherapy is any more or less effective among patients who also receive radiotherapy. (warwick.ac.uk)
  • Overall, 81% of women received anthracycline-based chemotherapy. (ascopost.com)
  • Although anthracycline-based chemotherapy has produced a modest improvement in DFS and OS over CMF (cyclophosphamide/methotrexate/fluorouracil) polychemotherapy regimens ( 1 ), this benefit seems to be largely confined to the subset of patients with amplification of the erb-B2/neu or topoisomerase II α genes or overexpression of the corresponding proteins ( 2 - 6 ). (aacrjournals.org)
  • Background: Use of anthracycline-based chemotherapy in patients with early breast cancer (EBC) has been well established but is often associated with cardiotoxicity. (uni-muenchen.de)
  • A total of 47 breast cancer patients who were scheduled to receive postoperative adjuvant anthracycline‑based chemotherapy, i.e., 5‑fluorouracil (5‑FU) + cyclophosphamide + epirubicin (FEC regimen), 5‑FU + cyclophosphamide + doxorubicin/pirarubicin (FAC regimen), cyclophosphamide + doxorubicin/pirarubicin (AC regimen) and cyclophosphamide + epirubicin (EC regimen), were entered in the study. (spandidos-publications.com)
  • Thus, LEM appears to be a useful oral adjuvant for patients receiving anthracycline‑based chemotherapy. (spandidos-publications.com)
  • However, patients on a